COSMETIC / DERMATOLOGICAL COMPOSITION

Abstract

The present invention relates to a pharmaceutical or dermatological composition and its use as a medicament. The present invention also relates to a cosmetic or dermatological composition, as well as to a care kit comprising the composition of the invention. The present invention finds particular application in the cosmetic, pharmaceutical, and veterinary fields.

Description

COSMETIC / DERMATOLOGICAL COMPOSITION FIELD OF INVENTION The present invention relates to a pharmaceutical or dermatological composition and its use as a drug or medical device. The present invention also relates to a cosmetic or dermatological composition, as well as to a care kit comprising the composition of the invention. The present invention also relates to an anti-aging cosmetic or dermatological composition, as well as to a care kit comprising the composition of the invention. The present invention also relates to a dermatological moisturizing cosmetic composition, as well as to a care kit comprising the composition of the invention. The present invention also relates to an ophthalmic composition, in particular to an ophthalmic composition for hydrating the cornea, as well as to a care kit comprising the composition of the invention. The present invention also relates to an anti-wrinkle cosmetic or dermatological composition, as well as to a care kit comprising the composition of the invention. Ref. 324607 The present invention also relates to a cosmetic or dermatological composition for use in the treatment of skin aging, for improving the appearance of the skin, as well as to a skin care kit comprising the composition. The present invention finds particular application in the cosmetic, pharmaceutical and veterinary fields. The present invention finds particular application in the joint pharmaceutical and veterinary field, in particular for the improvement and facilitation of movement and recovery of motor functions. The present invention finds particular application in the pharmaceutical and veterinary fields of vertebral movement, particularly for the improvement and facilitation of movement and recovery of motor functions. The present invention finds application in the dental field in particular in the improvement of gums and oral mucous membranes, fibrosis, for example, muscle fibrosis, adhesions, fibrosis of the digestive system, fibrosis associated with surgery, fibrosis of the heart, fibrosis of the brain, as an antioxidant, for example, for the treatment of oxidative stress. In the following description, references in brackets [] refer to the list of references presented at the end of the text. BACKGROUND OF THE INVENTION More than just an external covering, the skin is an organ in its own right, playing an essential role not only in protecting the body from external aggressions but also on an aesthetic and emotional level. The skin breathes, is sensitive to external aggressions, and reacts to both overall health and hormonal balance. Human skin consists of two layers: the epidermis and the dermis. The hypodermis, or subcutaneous connective tissue, varies considerably in thickness and is often functionally attached to the skin. It consists primarily of highly vascularized and innervated adipose tissue that acts as an interface with the underlying muscles and tendons. Sweat and sebaceous glands, as well as the integument, hair, and nails, are also located here. Healthy skin is well-hydrated skin. It is smooth, firm, supple, and elastic. The dermis is made up of a cellular structure whose main function is to ensure our skin's hydration. In the epidermis, layers of corneocytes, composed of protective keratin in a thousand-layered structure, act as a barrier to retain water and filter its evaporation. The skin is composed of approximately 70% water, or one-fifth of the water stored in our body. Water flows from the dermis to the epidermis. A cellular cushion made up of fatty substances based on lipids, and more specifically ceramides, prevents water from evaporating. This is what determines the natural moisturizing factor of our epidermis. Well-hydrated skin has a normal hydration level of between 13% and 15%. When this level drops to 10%, the skin is dehydrated.When the epidermis is not properly hydrated, due to a lack of water or essential fatty acids, the skin loses its flexibility and becomes dull. The first visible signs of aging appear in the texture, flexibility, color, transparency, and the appearance of wrinkles. In the field of facial aesthetics, age-related and hormonal changes in the skin are classically classified as atrophy, sagging, and fat accumulation. Atrophy corresponds to the significant thinning of the dermis and epidermis, resulting in a decrease in the number of cell layers in the epidermis and the thickness of the dermal connective tissue, as well as the relaxation of the hypodermis and subcutaneous tissues (fat, muscle), resulting in excess skin and ptosis. Sagging is visible in the cheeks and chin, as well as under the eyelids. Fat accumulation, linked to weight gain with age, is observed as swelling in the lower face and neck. These signs of aging can be accelerated and amplified over time by lifestyle factors such as smoking, alcohol consumption, or sun exposure. They are also often accompanied by dryness and roughness of the skin associated with a loss of elasticity, resulting in a decline in the quality of the skin tissue. The skin creases under mechanical pressure and takes longer to recover and return to its original state. These visual signs are merely the external reflection of these internal, age-related changes in the skin's structure. The decrease in the thickness of the epidermis with age results in a reduction in the multiplication of cells in the basal layer, due to a reduction in the number of epidermal cell layers, an alteration of the quantitative, structural, organizational and functional extracellular matrix, both on proteins and on glycosaminoglycans (GAGs) and proteoglycans (PGs) and the appearance of wrinkles. Among these (GAGs), hyaluronic acid (HA) plays a central role in maintaining hydration at all levels of the skin layers and its decrease is correlated with the appearance of wrinkles and with heparan sulfates (HS) in the regulation of the natural balance of tissue homeostasis and ensures a quadruple role as a stabilizing element, protection of the matrix architecture, storage and regulator of the bioavailability of cell communication factors in the microenvironment, both in the epidermis and in the dermis or hypodermis. With the aim of reducing the unsightly effects associated with skin alterations and aging, many procedures have focused on preventing, delaying, and improving various elements, both proteins and glycosaminoglycans (GAGs), present in the skin. Specifically, one procedure may attempt to induce an increase in their synthesis, delaying their degradation, by introducing products capable of replacing endogenous products but more resistant to degradation. The introduction of stimulants for the synthesis of matrix proteins, such as collagen or elastin, also improves the skin's performance at a mechanical and aesthetic level. Another possibility is the use of surfactants, which also have immediate visible effects on the skin by reducing fine lines and wrinkles and smoothing the skin, but these effects are very short-term and superficial. Many cosmetic formulations currently available contain active ingredients for treating skin aging. However, none of these formulations or active ingredients provide a lasting effect on the signs of aging and / or naturally restore or improve the skin's structure. Therefore, there is a real need in the state of the art to find a compound and / or composition that allows for the effective treatment of skin aging and / or the lasting improvement of the skin's appearance and / or the improvement of the skin's structure. There are also numerous cosmetic compositions in the state of the art, active ingredients for the treatment of skin aging, whose effect and / or benefit is limited in time, particularly by virtue of their rate of natural elimination and / or linked to the environment, thus limiting the duration of the effect that is linked to their presence in the area to be treated and / or in the skin. Therefore, there is a real need in the state of the art to find a compound and / or composition whose effect and / or benefit lasts over time, in particular a compound and / or composition capable of effectively treating skin aging and / or improving the appearance of the skin in a lasting way and / or improving the structure of the skin. Furthermore, known compositions and / or active ingredients do not effectively restore and / or improve skin structure. In particular, known compositions and / or active ingredients do not effectively restore and / or improve skin structure and / or prevent skin aging. Furthermore, the known compositions and / or active ingredients require, for relative effectiveness, a large number of applications and / or a prolonged treatment duration and / or a high frequency of application, particularly to the skin. The large number of applications and / or the prolonged treatment duration may potentially cause skin sensitization and lead to allergic reactions. Therefore, there is a real need in the state of the art to find a compound and / or composition that allows for the effective treatment of skin aging and / or the improvement of skin appearance, allowing in particular a limited number of applications in order to obtain an effect, particularly anti-aging and / or an improvement in skin appearance. Furthermore, known compositions and / or active ingredients generally have a superficial effect, for example, only temporary, lasting for a few hours, and do not provide a lasting and / or structural effect. Moreover, known compositions and / or active ingredients do not address or compensate for the underlying mechanisms and / or defects that cause skin aging. For example, hyaluronic acid is used in cosmetics as a moisturizing agent and also in medicine, for example, to treat vaginal or vulvar dryness. Hyaluronic acid is administered by injection, for example, into the labia majora to plump and rehydrate the skin and restore volume to the vulva and vaginal opening, thus protecting it and preventing the itching associated with dryness. Hyaluronic acid is also used as an injection to treat dry eyes, dry hair, and to rehydrate hair follicles, for example, in gel form or via microinjection, such as in mesotherapy, either alone or with cofactors or nourishing agents. Hyaluronic acid can also be used as an injection to enhance men's sexual performance by increasing the size of the glans.Examples of applications and / or uses of hyaluronic acid are illustrated in particular in the following documents: Hyaluronic acid-based modified materials for biomedical applications. Tiwari S, Bahadur P. Int J Biol Macromol. 2019 Jan; 121: 556-571. doi: 10.1016 / j.ijbiomac.2018.10.049. Electronic publication of October 12, 2018. Review [1]; Hyaluronic acid, a promising skin-rejuvenating biomedicine: A review of recent updates and preclinical and clinical research on cosmetic and nutricosmetic effects. Bukhari SNA, Roswandi NL, Wagas M, Habib H, Hussain F, Khan S, Sohail M, Ramli NA, Thu HE, Hussain Z. Int J Biol Macromol. December 2018; 120 (Part B): 1682-1695. doi: 10.1016 / j.ijbiomac.2018.09.188. doi: 10.1016 / j.ijbiomac.2018.09.188 [2] and Reduction in the development of postoperative adhesions. Diamond MP. Fertil Steril. October 2016; 106 (5): 994-997. doi: 10.1016 / j.fertnstert.2016.08.029.Electronic publication of September 10, 2016 Review [3]. However, although it has many applications, hyaluronic acid is useful in injections that involve the need for a doctor and a precise medical act that cannot be performed daily by a user. Therefore, there is a real need in the state of the art to find a compound and / or composition that allows for the effective treatment of tissue dryness, particularly of the skin, in particular a compound and / or composition, by local application, for example, by simple application to the tissue, for example, to the skin. There is also a real need in the state of the art to find a compound and / or composition that allows for the effective treatment of skin aging and / or that allows for an improvement in the appearance of the skin, through local application, for example, through a simple application to the tissue, for example, to the skin. It is also known that, over time, tissues, especially the skin, undergo a slow and irreversible evolution that leads to anatomical, histological, and functional changes. Many cosmetic formulations currently available contain active ingredients for treating skin aging. However, none of these formulations or active ingredients are able to act on or have a significant effect on the mechanism or mechanisms involved in the anatomical, histological, and / or functional changes of tissues, particularly the skin. Therefore, there is a real need in the state of the art to find a compound and / or composition that allows to act and / or have a significant effect on the mechanism or mechanisms involved in the anatomical, histological and / or functional changes of tissues, especially the skin. There are compounds in the prior art used in the therapeutic field capable of improving the tissue environment, for example, biocompatible polymers. In particular, those experienced in the art know that RGTA has an effect on the tissue repair and regeneration process by acting on the extracellular matrix, specifically by potentially protecting protein elements of the cellular and tissue microenvironment. It is also known for its soothing and analgesic properties, and possibly anti-fibrosis activities (patent document US06689741, US2014301972A1 [4], Reversal of abnormal collagen production in intestinal biopsies of Crohn's disease treated with regenerative agents. Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P. Gut.2004 Jan; 53 (1): 85-90 [5]), antioxidants (Perspectives on a novel route of regulation of premitochondrial apoptosis by a glycosaminoglycan mimetic. Yue XL, Lehri S, Li P, Barbier-Chassefiére V, Petit E, Huang QF, Albanese P, Barpy-Jar-Garcia, Carpy-Garcia D, Morin J. Cell Death Differ. May 2009; 16(5) : 770-81. doi: 10.1038 / cdd.2009.9 [6], Differential effect triggered by an RGTA-family heparan mimetic preventing oral mucositis without tumor protection. Mangoni M, Yue X, Morin C, Violot D, Frascogna V, Tao Y Opolon P, Castaing M, Auperin A, Biti G, Barritault D, Vozenin-Brotons MC, Deutsch E, Bourhis J. Int J. Radiat Oncol Biol Phys. 15 July 2009; 74 (4) : 1242-50. doi: 10.1016 / j.ijrobp.2009.03.006 [7]), scarring agents (RGTA OTR4120, a mimetic of heparan sulfate, is a possible long-term active agent for healing burned skin. Kerros ME, Petit E, Barritault D, Caruelle JP, Kern PJ Biomed Mater Res A. Jan 2007 80(1) : 75-8) that promotes skin healing and for the treatment of pain (patent paper EP1677807 [9]). These activities may be due in particular to the ability of these compounds to inhibit certain glycanases, e.g., heparanase, heparitinases, chondroitinases, and hyaluronidases (synthetic heparin-like polymers, called RGTA, mimic the biological effects of heparin in vitro. Rouet V, Meddahi-Pelle A, Miao HQ, Vlodavsky I, Caruelle JP, Barritault D. J Biomed Mater Res A. 2006 Sep 15; 78(4):792-7

[10] , EP1677807 [9], patent document US06689741, US2014301972A1 [4]), to inhibit elastase (protection of FGF and inhibition of elastase in human neutrophils by carboxymethyl benzylamide sulfonate dextran derivatives. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. Int J Biol Macromol. February 1996; 18 (1-2) : 141-5

[11] , collagenases, plasmin (the enzymatic activity of human plasmin is inhibited by chemically modified dextrans.Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck W, Caruelle JP. J Biol Chem. September 22, 2000; 275 (38): 29383-90

[12] ) and a plasminogen activator or calpain (heparan sulfate mimetics modulate calpain activity during rat soleus muscle regeneration. Zimowska M, Szczepankowska D, Streminska W, Papy D, Tournaire MC, Gautron J, Barritault D, Moraczewski J, Martelly I. J Cell Physiol. August 2001; 188 (2): 178-87

[13] ), to protect themselves at the level of sites where they bind (sites described in the literature as the heparan sulfate binding site or Heparan / heparin binding sites) from matrix proteins (growth and cell communication factors, namely VEGF and TGFbeta (RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to the healing of patients.Barritault D, Gilbert-Sirieix M, Rice KL, Siñeriz F, Papy-Garcia D, Baudouin C, Desgranges P, Zakine G, Saffar JL, van Neck J. Glycoconj J. June 2017; 34 (3): 325 - 338. doi: 10.1007 / S10719-016-9744-5

[14] . However, RGTAs are particularly useful during the treatment of large lesions and, in general, remain expensive compounds that cannot be used in the usual way, particularly in cosmetics. Therefore, there is a real need to find a new compound, a new composition, a treatment that allows us to treat tissue aging, particularly of the skin, and / or increase the effectiveness of known compositions while reducing their cost. There is also a real need in the state of the art to find a compound and / or composition that allows to act and / or have a significant effect on the mechanism or mechanisms involved in the anatomical, histological and / or functional changes of tissues, particularly of the skin, linked to aging, while at a reduced cost. BRIEF DESCRIPTION OF THE INVENTION The object of the present invention is precisely to satisfy these needs by providing a pharmaceutical composition, preferably a cosmetic or dermatological composition comprising a biocompatible polymer of the following general formula (I) AaXxYy (I) in which: A represents a monomer, X represents a group -R1COOR2 or -Rg(C=0)Rio, And it represents an O- or N-sulfonate group and corresponds to one of the following formulas: -R3OSO3R4, -RsNSO3R6, RvSOjRs in which: Ri, R3, R3 and Rg independently represent an optionally branched and / or unsaturated aliphatic hydrocarbon chain and optionally containing one or more aromatic rings, with the exception of benzylamine and benzylamine sulfonate; R2, R4, Re and Rs independently represent a hydrogen atom or a cation. R? and Rio independently represent a bond, an optionally branched and / or unsaturated aliphatic hydrocarbon chain, a represents the number of monomers, x represents the degree of substitution of monomers A by x groups, y represents the degree of substitution of monomers A by Y groups, and hyaluronic acid. Advantageously, it has been surprisingly shown that the combination of biocompatible polymers of general formula (I) as defined above, also referred to as RGTA herein, and hyaluronic acid makes it possible to synergistically treat and / or prevent the aging of biological tissues. In particular, it has been shown that the composition according to the invention advantageously allows preventing, reducing, eliminating or limiting the effects of age on the appearance of the skin, whether chronobiological or accelerated, for example, by external aggressions, for example, due to exposure to radiation, for example, UVA, UVB and / or ionizing rays. It has also been surprisingly demonstrated that the effects obtained are visible and long-lasting. In particular, the composition according to the invention has been shown to advantageously allow for a visible and lasting reduction of the signs and marks of aging, for example, a reduction in wrinkles and expression lines, advantageously improving the appearance of the skin, which can advantageously have a rejuvenated appearance, a more beautiful skin, for example, brighter, more supple, firmer, and also tighter skin. In particular, the composition according to the invention has been shown to advantageously protect tissues, such as skin and / or mucous membranes, from external attacks, such as those caused by exposure to radiation, including UVA, UVB, and / or ionizing rays, cold, etc. Specifically, the composition according to the invention has been shown to advantageously prevent and / or protect tissues, such as skin and / or mucous membranes, from dryness. For example, the composition according to the invention has been shown to advantageously and synergistically provide protective and / or moisturizing effects on mucous membranes, thereby reducing the effects associated with tissue dryness. It has also been shown that the composition according to the invention advantageously allows, in particular by improving the properties of the tissues, for example, hydration, flexibility, etc., facilitating joint and tendon movements, improving intervertebral movements, in particular improving the properties of the intervertebral discs and generally promoting functional tissue recovery. Furthermore, it has been shown that the combination of biocompatible polymers of general formula (I) with hyaluronic acid according to the invention can be used / applied to any biological tissue, for example, by local application, such as to the skin and / or the surface of biological tissues. In addition, it has been shown that the combination of biocompatible polymers of general formula (I) with hyaluronic acid according to the invention can also be used / applied by injection. It has also been surprisingly and unexpectedly demonstrated that the combination of biocompatible polymers of general formula (I) with hyaluronic acid according to the invention exhibits a strong synergistic effect observed in the functional and scar recovery of tissues. Furthermore, it has also been surprisingly and unexpectedly demonstrated that the combination of biocompatible polymers of general formula (I) with hyaluronic acid according to the invention has a synergistic effect in the treatment of scars, for example, scar treatment, aesthetic scar treatment. Furthermore, it has been surprisingly shown that the combination of biocompatible polymers of general formula (I) with hyaluronic acid according to the invention has a lasting effect over time, in particular allowing both the duration of the action of the combination to be prolonged by delaying the elimination and advantageously also allowing the restoration of the synthesis and / or production of biological elements, for example, proteins, of a constituent of the extracellular matrix whose production is reduced and / or altered with aging, for example, of biological tissue. In this document, "tissue" means any biological tissue of a mammal known to those skilled in the art. This may include, for example, connective tissue, muscle tissue, nervous tissue, bone tissue, cartilage, and / or epithelial tissue. It may also include, for example, any biological tissue from any mammalian organ or organelle known to those skilled in the art. This may include, for example, tissue of the digestive tract or system, tissues of the gastrointestinal system or tract, the digestive system of feeding and excretion, the genital tract, the reproductive system ... MA / a / ZUZI / UUOO I z reproductive, the optical, olfactory or auditory system, the sensory system, the circulatory and / or cardiovascular system, the respiratory system, the muscular system, the locomotor system. This may be, for example, gastric tissue, oral tissue, cornea, tympanic tissue, cochlear tissue, skin, bone tissue, cartilage tissue, tendon tissue, nervous tissue, spinal cord, nerve fiber, retina, arteries and / or vessels, tissue of the digestive or renal system, urinary tract and / or any biological tissue that allows the passage of biological fluids, for example, any biological tissue that allows the passage of biological fluids known to those experienced in the technique, for example, Schlemm's duct or the lymphatic system. As used herein, "scar" means any tissue response to injury of any nature, duration, or intensity that results in inflammation and the formation of scar tissue that is not identical to the original tissue. This may include, for example, any scar tissue formation that is not identical to the original tissue known to those experienced in the technique. It may also include, for example, scar tissue that is not identical to the original tissue, where a trace and / or fibrosis forms, for instance, with aspects and properties different from the original tissue, such as shape, flexibility, adherence, and / or thickness. In the present case, a monomer is understood to mean, for example, a monomer selected from the group comprising sugars, esters, alcohols, amino acids, or nucleotides. In the present, the A monomers that constitute the basic components of the polymers of formula I can be the same or different. In the present, the A monomers can be independently of the monomers of the following formula: wvO / UUOO I ¿ wherein Rg and Rio independently represent an oxygen atom, an optionally branched and / or unsaturated aliphatic hydrocarbon chain, a heteroaryl group independently comprising one or more oxygen and / or nitrogen atoms, an aldehyde function, a carboxylic acid group, a diol, a substituted diol, a group of formula -Rn-(X)n-Ri2 wherein Rn represents an optionally branched and / or unsaturated aliphatic carbon chain from C1 to C4, X represents a heteroatom chosen from oxygen and nitrogen, n is an integer from 1 to 4, and R12 is a hydrogen atom, an optionally branched and / or unsaturated aliphatic hydrocarbon chain, a heteroaryl group independently comprising one or more oxygen and / or nitrogen atoms, an aldehyde function, a carboxylic acid group, a diol, a substituted diol. Currently, the combination of monomers can allow the formation of a polymeric structure, for example, a polymeric structure of the polyester, polyalcohol, polysaccharide, nucleic acid or protein type. Currently, among the polyesters, there may be, for example, copolymers of biosynthesis or chemical synthesis, for example, aliphatic polyesters or of natural origin, for example, polyhydroxyalkanoates. Currently, polysaccharides and their derivatives can be of bacterial, animal, fungal, and / or plant origin. They can be, for example, single-chain polysaccharides, such as polyglucoses, dextran, cellulose, and beta-glucan, or other monomers comprising more complex units, such as xanthan gums, mannose, and glucuronic acid, or glucuronans and glucoglucuronan. Currently, polysaccharides of plant origin can be single-chain, for example, cellulose (glucose), pectins (galacturonic acid), fucans, starch, or more complex such as alginates (galuronic and mannuronic acid). Currently, polysaccharides of fungal origin can be, for example, stereoglucan. Currently, polysaccharides of animal origin can be, for example, chitins or chitosan (glucosamine). In the present, the A monomers that constitute the basic elements of the polymers of formula I can be advantageously identical. In the present, the A monomers that constitute the basic elements of the polymers of formula I can advantageously be glucose. The number of monomers A defined in formula (I) by a can be such that the mass of such polymers of formula (I) is approximately between 2000 and 6000 daltons, which corresponds, for example, to at least 10 glucose monomers. For example, the mass of such polymers of formula (I) can be between approximately 3000 and 6000 daltons, which corresponds to 12 to 20 glucose monomers. The number of monomers A defined in formula (I) by a can also be such that the mass of such polymers of formula (I) is less than approximately 2,500,000 daltons (corresponding to 7,000 glucose monomers). Advantageously, the mass of such polymers of formula (I) can be from 3,000 to 250,000 daltons, for example, from 3,000 to 6,000 daltons, or, for example, from 20,000 to 250,000 daltons, or, for example, from 75,000 to 150,000 daltons. In the present, in the group -R1COOR2 representing X, Ri can be an alkyl from Ci to Ce, for example, a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group and R2 can be a bond, an alkyl from Ci to Ce, for example, a methyl, an ethyl, a butyl, a propyl, a pentyl, or an R21R22 group in which R21 is an anion and R22 is a cation selected from the alkali metal group. Preferably, group X is the group of formula -R1COOR2 in which Ri is a methyl group -CH2- and R2 is an R21R22 group in which R21 is an anion and R22 is a cation chosen from the alkali metal group, preferably group X is a group of formula -CH2-COO- or carboxymethyl. In the present, in the group - Rg(C=0)Rio which represents X, R9 can be an alkyl from Ci to Ce, for example, a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group and Rio can be a bond, alkyl from Ci to Ce, for example, methyl, ethyl, butyl, propyl, pentyl, hexyl. The degree of substitution of the set of monomers A by groups X defined in the general formula (I) by x can be from 10 to 150%, from 40 to 80% and preferably on the order of 50% or 60%. In the present, in the group corresponding to one of the following formulas -R3OSO3R4, -R5NSO3R6, -R7SO3R8 and representing group Y, R3 can be a bond, an alkyl from Ci to Cg, for example, a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group, R5 can be a bond, an alkyl from Ci to Cs, for example, a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group, R? can be a bond, an alkyl from Ci to Ce, for example, a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group, R4, Re and Rs can independently be a hydrogen atom or a cation M+, for example, M+ can be an alkali metal. Preferably, group Y is the group of formula -R7SO3R8, in which R7 is a bond and Rg is an alkali metal selected from the group consisting of lithium, sodium, potassium, rubidium, and cesium. Preferably, group Y is a -SO3, -SO3“Na+ group. The degree of substitution of the set of monomers A by groups Y defined in the general formula (I) by y can be from 10 to 170%, from 30 to 150%, from 55 to 160%, from 55 to 85%, from 120 to 160% and preferably on the order of 70, 140 or 150%. In the present definition of the degrees of substitution above, a degree of substitution x of 100% means that each monomer A of the polymer of the invention statistically contains one group X. A degree of substitution y of 100% means that each monomer of the polymer of the invention statistically contains one group Y. Degrees of substitution greater than 100% reflect the fact that each monomer statistically carries more than one group of the type considered; conversely, degrees of substitution less than 100% reflect the fact that each monomer statistically carries less than one group of the type considered. Polymers can also comprise functional chemical groups, called Z, other than X and Y. In the present, the Z groups can be the same or different and can be selected independently of the group consisting of amino acids, fatty acids, fatty alcohols, ceramides or derivatives thereof or targeted nucleotide sequences. The Z groups can also represent identical or different active agents. These can be, for example, therapeutic agents, diagnostic agents, an anti-inflammatory, an antimicrobial, an antibiotic, a growth factor, an enzyme, an antioxidant compound, polyphenols, tannins, anthocyanins, lycopene, terpenoids, and resveratrol. In this formulation, group Z can advantageously be a saturated or unsaturated fatty acid. It can be, for example, a fatty acid selected from the group comprising acetic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, cerotic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, trans-vaccenic acid, linoleic acid, linolelaidic acid, α-linolenic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, eicosapentaenoic acid, clupanodonic acid, or docosahexaenoic acid. Preferably, the fatty acid is acetic acid. In the present formulation, group Z can advantageously be an L- or D-series amino acid selected from the group comprising alanine, asparagine, and an aromatic chain, for example, tyrosine, phenylalanine, tryptophan, thyroxine, or histidine. Preferably, the amino acid is phenylalanine. Currently, the Z group can be an antioxidant, for example, vitamin A, C, E, B9, B6, glutathione, selenium, polyphenols, for example, catechins, for example, green tea, flavonoids, tannins, anthocyanins, for example, red fruits, lycopene, terpenoids and resveratrol. Currently, group Z may consist of anti-aging compounds, for example, retinoids. Advantageously, Z groups can confer additional biological or physicochemical properties to polymers. For example, Z groups can increase the solubility or lipophilicity of a polymer, allowing, for example, better diffusion or tissue penetration. Advantageously, the Z groups can give the polymers additional biological or physicochemical properties. Thus, for example, when the Z group is chosen from an antioxidant or an anti-aging compound, the polymers of the invention can advantageously carry these compounds and therefore provide an additional and / or complementary biological effect. The polymers in which Z is present correspond to the following formula II: AaXxYyZz (II) in which, A, X, Y, a, x, y are as defined above and yz represents the degree of substitution by Z groups. In the present, the degree of substitution of Z groups represented by z can be between 1 and 50%, from 10 to 25%, preferably equal to 15, 20 or 25%. Groups X, Y, and Z can be independently attached to monomer A and / or independently attached to each other. When at least one of the groups X, Y, and Z is independently attached to a group X, Y, or Z other than the first, one of those groups X, Y, or Z is attached to monomer A. Therefore, the Z groups can be covalently fixed directly to the A monomers or covalently fixed to the X and / or Y groups. In the present invention, the Z groups can also be conjugated to polymers of formula AaXxYy by means of bonds other than covalent bonds, for example, by ionic bonds, hydrophilic bonds, or hydrophobic bonds. The polymers of the invention can then constitute a Z vectoring system. In the present case, the polymer may be, for example, an RGTA selected from the group comprising compounds OTR4120, OTR41201, OTR41202, OTR41203, OTR41205, OTR41210, OTR41301, OTR41302, OTR41303, OTR41305, OTR41310, OTR3131. In the present case, the polymer may be, for example, an RGTA selected from the group comprising compounds OTR41201, OTR41202, OTR41203, OTR41205, OTR41210, OTR4120, OTR4122, OTR4125, OTR41301, OTR41302, OTR41303, OTR41305, OTR41310, OTR3131, OTR4132, OTR4135, OTR415 with the characteristics mentioned in Table 1 below. Table 1: Polymers of the AaXxYy and AaXxYyZz families in which A is glucose (PM 180D), X is Carboxymethyl (PM 58 D) Y: SO3 (PM 80D) and Z Acetate (PM 43D) or phenylalanine (PM 165D). Polymer A: glucose X -CH2COO Y -SO3 Z -OCCH3 z phenylalanine RGTA Name Starting Dextran Polymer (MW in Daltons) Average Molecular Weight M + / -15% % Substitution CM / glucose % Substitution SO4 / glucose) % Substitution OCCH3 / glucose CMDS OTR41201 1 500 3 000 60+ / -20 150+ / -20 0 CMDS OTR41202 3 000 6 000 60+ / -20 150+ / -20 0 CMDS OTR41203 5 000 10 000 60+ / -20 150+ / -20 0 CMDS OTR41205 10 000 20 000 60+ / -20 150+ / -20 0 CMDS OTR41210 20,000 40,000 60+ / -20 150+ / -20 0 CMDS OTR4120 40,000 80,000 60+ / -20 150+ / -20 0 CMDS OTR4122 110,000 220,000 60+ / -20 150+ / -20 0 CMDS OTR4125 250 000 500 000 60+ / -20 150+ / -20 0 CMDSA OTR41301 1 500 3 000 60+ / -20 140+ / -20 20+ / -5 CMDSA OTR41302 3 000 6 000 60+ / -20 140+ / -20 20+ / -5 CMDSA OTR41303 5,000 10,000 60+ / -20 140+ / -20 20+ / -5 CMDSA OTR41305 10,000 20,000 60+ / -20 140+ / -20 20+ / -5 CMDSA OTR41310 20,000 40 000 60+ / -20 140+ / -20 20+ / -5 CMDSA OTR4131 40,000 80,000 60+ / -20 140+ / -20 20+ / -5 CMDSA OTR4132 110,000 220,000 60+ / -20 140+ / -20 20+ / -5 CMDSA OTR4135 250,000 500,000 60+ / -20 140+ / -20 20+ / -5 CMDSP OTR415 5000 60+ / -20 70+ / -15 - 15+ / -5 MA / a / ZUZI / UUOO I z The composition herein may comprise a concentration of 0.1 to 100 pg / ml by weight of biocompatible polymer relative to the volume of the composition. For example, the composition may comprise a preferred concentration of 1 to 10 pg / ml by weight of biocompatible polymer relative to the total volume of the composition. The composition can be formulated and / or adapted according to its administration. For example, for topical administration, the composition may comprise 0.1 to 100 pg / ml by weight of biocompatible polymer relative to the total volume of the composition. For example, for parenteral administration, the composition can be administered to deliver a dose of biocompatible polymer of 0.1 to 5 mg per kilogram of body weight. Advantageously, the molecular weight of the biocompatible polymers present in the composition can be chosen according to the route of administration of the composition and the target, for example, epidermis, dermis, mucous membranes, cornea, tympanic membrane, organs, intra-articular fluid, infra-ocular. For example, for topical or oral administration, the molecular weight may be from 3,000 to 6,000 Daltons to promote passage across basement membranes. For example, for administration by intradermal, subcutaneous, intrathecal, or intramuscular injection, or injection into muscles, organs, or intra-articular spaces, the molecular weight may be between 6,000 and 2,500,000 Daltons, preferably between 20,000 and 250,000 Daltons, and, for example, from 75,000 to 150,000 Daltons. Advantageously, when the molecular weight of the biocompatible polymer is between 3000 and 6000 Daltons, it can advantageously allow, during topical application, for example, to an epithelium, for example, of mucous membranes or skin, a passage of the basal lamina, advantageously allowing better administration and promoting a longer-distance effect. Advantageously, when the molecular weight of the biocompatible polymer is between 3,000 and 2,500,000 Daltons, it can advantageously allow for better availability and shelf life regardless of the tissue location. In this document, hyaluronic acid is understood to mean any hyaluronic acid known to those experienced in the technique, for example, a non-sulfated linear glycosaminoglycan composed of repeating units of D-glucuronic acid and N-acetyl-D-glucosamine. It may be, for example, hyaluronic acid (HA) in its acid form or in the form of a salt (hyaluronate), of cross-linked hyaluronic acid. HA is a non-sulfated linear glycosaminoglycan composed of repeating units of D-glucuronic acid and N-acetyl-D-glucosamine (Tammi R., Agren UM., Tuhkanen AL., Tammi M. Hyaluronan metabolism in skin. Progress in Histochemistry & Cytochemistry. 29(2): 1-81, 1994

[15] ). It could be, for example, hyaluronic acid with average molecular weight fractions of 5,000 to 3,000,000 Daltons, preferably between 50,000 and 2,000,000 Daltons. Currently, hyaluronic acid can be obtained by any method known to those experienced in the technique.These may include, for example, methods described in the journal Hyaluronan Fragments: An Information-Rich System (R. Stern et al., European Journal of Cell Biology 58 (2006) 699-715

[16] ). It may also be commercially available natural or modified hyaluronic acid, regardless of its name and / or molecular weight, for example, commercial hyaluronic acid selected from Hyactive CPN; Cristalhyal; Nutra AH; Oligo AH; Factor D; Hialuderm; Juvelift; Restylane; Revitacare, although this list is not exhaustive. It may also be hyaluronic acid marketed by Contipro (https: / / www.contipro.com / portfolio / manufacturer-of-antiageing-cosmetic-raw-materials / HyActive) and / or Givaudan (https: / / www.givaudan.com / fragances / activebeauty / products / cristalhyal%C2%AE-range). In this formulation, the composition may comprise a concentration of 0.1 to 5% by weight of hyaluronic acid relative to the total weight of the composition. For example, the composition may comprise a concentration of 0.5% to 2.5% by weight of hyaluronic acid relative to the total weight of the composition. Currently, the composition can be formulated and / or adapted according to its administration. For example, for topical administration, the composition may comprise from 0.5% to 2.5% by weight of hyaluronic acid relative to the total weight of the composition. For example, for parenteral administration, e.g., intra-articular, e.g., into the synovial fluid of the knee or the synovial fluid of the trapeziometacarpal or metacarpophalangeal joint, e.g., for rhizarthrosis, or e.g., intratendinous, e.g., for tendinitis, the composition can be administered to deliver a dose of 1 mg to 20 mg of hyaluronic acid per ml of composition. For example, for parenteral administration, the composition may comprise a concentration of 0.1 to 20 mg / ml of hyaluronic acid. Advantageously, the molecular weight of the biocompatible polymers present in the composition can be chosen according to the route of administration of the composition. For the purposes of this document, "pharmaceutical composition" means any form of pharmaceutical composition known to those skilled in the art. A pharmaceutical composition may be, for example, a composition for topical application, an injectable solution, for example, for local or systemic injection, for example, in physiological saline solution, in glucose solution for injection, in the presence of excipients, for example, dextrans, for example, at concentrations known to those skilled in the art, for example, from micrograms to a few milligrams per milliliter. The pharmaceutical composition may be, for example, a medicinal product intended for oral administration chosen from the group comprising a liquid formulation, an effervescent oral dosage form, an oral powder, a multiparticle system, or an orodispersible dosage form. For example, when the pharmaceutical composition is for oral administration, it may be in the form of a liquid formulation selected from the group comprising a solution, syrup, suspension, or emulsion. When the pharmaceutical composition is in the form of an effervescent oral dosage form, it may be in a form selected from the group comprising tablets, granules, and powders. When the pharmaceutical composition is in the form of an oral powder or a multiparticulate system, it may be in a form selected from the group consisting of pearls, granules, mini-tablets, and microgranules. When the pharmaceutical composition is in the form of an orodispersible dosage form, it may be in a form selected from the group consisting of orodispersible tablets, lyophilized wafers, thin films, a chewable tablet, a caplet, a capsule, or a medicated chewing gum. According to the present invention, the pharmaceutical composition may be a pharmaceutical composition for oral administration, for example, buccal and / or sublingual, for example, selected from the group comprising buccal or sublingual tablets, toothpastes, dental buccal adhesive dressings, lozenges, drops, spray solution. According to the present invention, the pharmaceutical composition may be a pharmaceutical composition for intraurinary administration. Advantageously, when the pharmaceutical composition is suitable for intraurinary administration, it can be awaited after administration to the bladder epithelium. According to the present invention, the pharmaceutical composition may be a dermatological or cosmetic composition, for example, for topical administration and / or application. The dermatological or cosmetic composition according to the invention may comprise one or more dermatologically and / or cosmetically acceptable carriers. Herein, a dermatologically and / or cosmetically acceptable carrier means any cosmetic carrier known to those skilled in the art; it may be, for example, any cosmetic carrier that can be listed in the INCI dictionary (International Nomenclature of Cosmetic Ingredients) published by the PCPC (Personal Care Products Council). The dermatological or cosmetic composition according to the invention may comprise one or more adjuvants known to those skilled in the art. It may be, for example, one or more adjuvants selected from ester-type agents, moisturizing agents, emollients, inorganic thickening agents, organic thickening agents, associative or non-associative, water-soluble and fat-soluble organic sunscreens, mineral sunscreens, silicone compounds, perfumes, preservatives, ceramides and pseudoceramides, vitamins and provitamins, proteins, sequestering agents, alkalizing agents, acidifying agents, reducing agents, oxidizing agents, mineral fillers, colorants, or any other adjuvant that may be listed in the INCI (International Nomenclature of Cosmetic Ingredients) dictionary published by the PCPC (Personal Care Products Council). According to the invention, the cosmetic composition can, for example, be in any form known to those skilled in the art. It can be, for example, an oil-in-water emulsion, a water-in-oil emulsion, a water-in-silicone emulsion, a multi-emulsion emulsion, a microemulsion, a nanoemulsion, a solid emulsion, an aqueous or hydroalcoholic gel, a cream, a gel, a milk, a lotion, an ointment, an oil, a balm, a salve, a mask, a powder, a soaked carrier (e.g., a transdermal patch, a soaked dressing), an aqueous lotion, a spray, or a hydroalcoholic and / or wax, shampoo, conditioner, mask, serum, or hair lotion. Preferably, the cosmetic composition according to the invention can be presented in a form chosen from among a cream, a gel, an ointment, or an oil. The cosmetic or dermatological composition of the invention can be obtained by any appropriate process known to those skilled in the art of manufacturing a cosmetic and / or dermatological composition. According to the present invention, the pharmaceutical composition may be a pharmaceutical composition for administration via the respiratory or nasal route, for example, in the form of an aerosol. According to the present invention, the composition may be a composition for the nasal or respiratory tract, for example, selected from the group comprising nasal drops, nasal spray, nasal powder, aerosols, for example, compressed gas nasal sprays and / or aerosols or nebulizers. Advantageously, when the pharmaceutical composition is appropriate for a nasal or respiratory route, it may be advantageously for bronchopulmonary purposes. According to the present invention, the composition of the present invention may be a composition for parenteral administration, for example, subcutaneous, intramuscular, intravenous, intrathecal. According to the present invention, the composition may be an ocular composition, selected, for example, from the group comprising drops, gel, and cream. It may be, for example, eye drops, for example, for the treatment of the cornea, by application of the composition to the surface of the eye, by transcorneal injection, for example, in the treatment of Decemet's membrane, or also for the treatment of glaucoma to reduce Schlemm's ductal fibrosis by injection, for example, into the aqueous or vitreous humor, or by topical application, for example, to the cornea. Advantageously, when the composition is used in topical application to the cornea, it can be advantageously useful at the transcorneal level, advantageously if the composition comprises polymers of small molecular weights, for example, comprising between 2000 and 6000 Daltons. The composition of the present invention may also comprise at least one other active ingredient, particularly another therapeutically active ingredient, for example, for simultaneous, separate, or staggered use depending on the galenic formulation used. This other ingredient may be, for example, an active ingredient used in the treatment of timely diseases, or a vitamin, an analgesic, etc. Currently, the administration of the biocompatible polymer and hyaluronic acid can be simultaneous, sequential, or concomitant. According to the invention, at least one of the administrations can be carried out topically, orally, by inhalation, or by injection. The two administrations can be carried out in the same or different ways. For example, the biocompatible polymer and hyaluronic acid can be administered topically. The administration method can also depend on the area and / or biological tissue being treated. According to the invention, the composition can be administered, for example, only once. According to the invention, the composition can also be administered, for example, daily, twice a day, weekly, or less frequently. It can be administered, for example, once a day, twice a day, or less frequently, such as once every two days or once a week. According to the invention and the method of administration, the composition may be, for example, for a cream administered daily, twice daily, weekly, or less frequently. For example, this could be once a day, twice a day, or less frequently. According to the invention, the composition can be administered, for example, for a period of 1 day to 3 months, for example, for 2 months. For example, the composition can be administered for a period of 3 or 6 months, for example, with a frequency of administration every day. For example, when the composition is in injectable form, the composition can be administered with a frequency of administration every 3 or 6 months or less. It has been surprisingly demonstrated that combining a biocompatible polymer with the formula AaXxYy or AaXxYyZz and natural or modified hyaluronic acid allows for a surprisingly advantageous synergistic effect in treatment. In particular, the resulting effect has been shown to be both a synergy that surpasses the individual effects of each compound and, advantageously, an increase in the duration of these effects. Furthermore, it has been surprisingly demonstrated that the duration of the effects can be increased even further, for example, by using multiple administrations, such as by identical or different routes of administration and / or a special dosage. For example, administration of the composition according to the invention by injection, such as subcutaneous or intramuscular injection, can be followed by application of the composition according to the invention via the skin, such as topical application. In the present case, the composition according to the invention can be administered by different routes simultaneously, successively or concomitantly. According to the invention, at least one of the administrations can be carried out by oral or topical application or by injection. The two administrations can be carried out in the same manner or in different ways. For example, the composition can be administered by injection followed by topical application of the composition. The administration can also depend on the area and / or biological tissue to be treated. Advantageously, when the composition can be administered by injection followed by topical application of the composition, the composition for topical application can be in a form chosen from a cream, gels, or serum. Advantageously, it has been surprisingly shown that the topical application of the composition in a form chosen from cream, gels or serum allows, surprisingly, for a further prolongation of the biological effect due to the first administration. An object of the present invention is also a cosmetic or dermatological composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and natural or modified hyaluronic acid for use in the non-therapeutic cosmetic treatment of skin aging, wrinkles and / or expression lines, for scalp protection and hair regeneration. The biocompatible polymer is as defined above. Hyaluronic acid is as defined above. According to the invention, the patient can be any mammal. It could be, for example, an animal or a human being. According to the invention, the mode and / or route of administration of the biocompatible polymer can be as defined above. According to the invention, the mode and / or route of administration of hyaluronic acid can be as defined above, preferably by injection into biological tissue. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the frequency of hyaluronic acid administration can be as defined above. An object of the present invention is also a cosmetic or dermatological composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and natural or modified hyaluronic acid for use in the prevention and / or non-therapeutic cosmetic treatment of hair loss and / or alopecia. The biocompatible polymer is as defined above. Hyaluronic acid is as defined above. According to the invention, the mode and / or route of administration of the biocompatible polymer can be as defined above. According to the invention, the mode and / or route of administration of hyaluronic acid can be as defined above, preferably by injection into biological tissue. According to the invention, the cosmetic or dermatological composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid can be a composition for topical and / or hair application, for example, a cream. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the frequency of hyaluronic acid administration can be as defined above. An object of the present invention is also an anti-aging cosmetic or dermatological composition and / or for the protection of the skin from external aggressions and / or for the treatment and / or prevention of skin aging comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid. The biocompatible polymer is as defined above. Hyaluronic acid is as defined above. According to the invention, the patient can be any mammal. It could be, for example, an animal or a human being. According to the invention, the mode and / or route of administration of the biocompatible polymer can be as defined above. According to the invention, the mode and / or route of administration of hyaluronic acid can be as defined above, preferably by injection into biological tissue. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the frequency of hyaluronic acid administration can be as defined above. An object of the present invention is also a cosmetic treatment method comprising applying to the skin a cosmetic composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid. The biocompatible polymer is as defined above. Hyaluronic acid is as defined above. According to the invention, the patient can be any mammal. It could be, for example, an animal or a human being. According to the invention, the mode and / or route of administration of the biocompatible polymer can be as defined above. According to the invention, the mode and / or route of administration of hyaluronic acid can be as defined above, preferably by injection into biological tissue. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the frequency of hyaluronic acid administration can be as defined above. In the present case, cosmetic treatment is understood to mean a non-therapeutic cosmetic treatment. According to the invention, the non-therapeutic cosmetic treatment can be an anti-aging cosmetic treatment, a cosmetic treatment for the prevention of skin aging, a cosmetic treatment for skin aging and / or a cosmetic treatment for mature skin. In fact, as mentioned above, it has been surprisingly demonstrated that the composition according to the invention allows synergistically stimulating tissue hydration, advantageously over time and linked in particular to the creation of a better tissue environment that surprisingly prolongs the effect of hyaluronic acid, while reducing the activity of glycanases and stimulating the response of proximal cells, advantageously and surprisingly allowing a neo-synthesis of the constituents of the extracellular matrix, these constituents being of better quality, while restoring the distribution and polarity of the matrix. For this application, it is possible, for example, to use the dosage forms described above. Therefore, application to the skin can be performed according to the dosage form used. It may be, for example, a simple application on the skin or an application accompanied by a skin massage with the composition of the present invention. It may be, for example, a successive application of the composition according to the invention comprising a first application, for example, by cutaneous injection, of the composition according to the invention, followed by a topical application of such composition according to the invention. The application should preferably be done with a sufficient quantity of the composition, for example, to cover the entire surface of the skin being treated. This can be, for example, a classic application, such as a cream applied to the skin. It can also be, for example, applied as a treatment mask. The application can be, for example, a daily, weekly, or bimonthly application. This could be, for example, an application once a day, twice a day, or less frequently. It has also been surprisingly demonstrated that the composition according to the invention advantageously allows for more effective wrinkle filling, while avoiding any side effects compared to known products, such as collagen and / or botulinum toxin injections. Furthermore, the composition according to the invention has been shown to be useful as a filler, for example, for wrinkles, but also for injection in cosmetic treatments and / or as a filler, for example, for hydration and swelling, for example, in the genitals and / or sexual organs of men or women. Therefore, an object of the present invention is also the use of a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention as a filler and / or replacement, for example, for organs and / or biological tissue. Therefore, an object of the present invention is also the cosmetic use of a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention as a filler and / or filler for the skin. It has also been surprisingly demonstrated that the composition according to the invention advantageously improves the healing of biological tissue lesions, particularly by promoting tissue hydration and filling of the lesion. Specifically, it has been surprisingly demonstrated that the composition according to the invention advantageously promotes skin healing and / or improves the appearance of skin lesions, such as scars. Therefore, an object of the present invention is also the cosmetic use of a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention to improve the appearance of the skin, for example, scars. Therefore, an object of the present invention is also the cosmetic use of a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for the treatment of skin lesions. It has also been surprisingly shown that the composition according to the invention advantageously allows for improved healing of biological tissue injuries, in particular by promoting tissue hydration, preventing fibrosis formation, and filling the injury. In particular, it has been shown that the composition according to the invention advantageously allows accelerating the speed and physical quality of the scar tissue, in particular these mechanical properties, its flexibility and its hydration. Furthermore, it has been demonstrated, particularly in the examples, that the injuries treatable with the composition according to the invention can be due to any type of tissue damage, regardless of its origin, and can affect any type of tissue or organ. In particular, someone of ordinary skill in the art, in light of the following examples where a wide variety of injuries are effectively treated, readily understands and can, based on this knowledge, extrapolate to other tissue injuries treatable by the present invention. As used herein, tissue damage means any damage to any biological tissue of a mammal known to those skilled in the art. This may be, for example, damage to connective tissue, muscle tissue, bone tissue, cartilage, and / or epithelial tissue. It may be, for example, any injury to any organ or organelle of a mammal known to those skilled in the art. It may be, for example, injury to the tissues of the digestive tract, tissues of the gastrointestinal tract, the digestive system for food and excretion, the genital tract, the reproductive system, the olfactory or auditory system, the sensory system, the circulatory and / or cardiovascular system, the respiratory system, the muscular system, or the locomotor system. This may be, for example, injury to gastric tissue, oral injury, corneal injury, tympanic membrane injury, cochlear injury, skin injury (e.g., wound, chronic wound, e.g., diabetic wound).ulcerative wound, pressure ulcer, skin burn, necrotizing wound, venous wound, ischemic injury, e.g., ischemic necrosis, injury due to an infarction, e.g., a myocardial infarction, bone injury, e.g., a fracture, a fracture with bone defect, osteonecrosis (non-union bone fracture), osteochondral lesion, cartilage injury, tendon injury, surgical injury, injury due to a surgical operation, injury due to medical treatment, e.g., radiotherapy, nerve tissue injury, e.g., brain injury, injury due to tumor removal, spinal cord injury, injury to nerve fibers, e.g., of the locomotor and / or sensory system, respiratory system damage, e.g., lung damage, circulatory system damage, e.g., damage to arteries and / or vessels, digestive, hepatic, renal, urinary system damage. An object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or MA / a / ZUZI / UUOO I z treatment of tissue damage. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of tissue damage chosen from eye damage, vocal cord damage, joint injuries, disc injuries, tendon and / or ligament injuries, retinal injuries, for example, retinal detachment, injuries due to Behget's disease, surface injuries, for example, skin wounds, ulcers, for example, diabetic wound ulcers, stomach ulcers. It has also been shown that the composition according to the invention advantageously allows, after administration to a joint, to be a joint facilitator / moisturizer and / or a joint lubricant that advantageously allows to prevent and / or treat joint inflammation, prevent and / or treat arthritis and / or osteoarthritis. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of pathologies and / or conditions of the locomotor system. According to the invention, pathology and / or conditions of the locomotor system are understood to mean any pathology and / or condition known to someone of ordinary skill in the art that can modify and / or alter the functioning of the locomotor system. This could be, for example, a pathology of the joints, such as inflammation of the joints, osteoarthritis, or arthritis. This could be, for example, a pathology of the tendons or ligaments, such as inflammation, stretching, flattening, injury, rupture, or tearing. It could be, for example, a pathology at the level of the spine and / or intervertebral discs, such as displacement, flattening, compression, or crushing related to trauma, age, dehydration, etc. It has also been shown that the composition according to the invention advantageously allows, after administration to the eye, the filling and strengthening of the subretinal environment, particularly in retinal detachments, and advantageously the protection of the retinal microenvironment in dry and wet AMD, advantageously allowing the prevention and / or treatment of retinal lesions, for example, retinal detachment, and / or the treatment of age-related macular degeneration, dry age-related macular degeneration, and wet age-related macular degeneration. It has also been surprisingly shown that the composition according to the invention advantageously allows for improved tissue hydration. Furthermore, it has been demonstrated, particularly in the examples, that the composition according to the invention allows for the treatment and / or improvement of the hydration of all types of tissues and organs. In particular, a person of ordinary skill in the art, in light of the following examples in which a wide variety of tissues and organs are effectively treated, readily understands and can, based on this knowledge, extrapolate to other tissues and organs that can be treated by the present invention. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of tissue dryness. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of tissue dryness, selected in particular from the following: dryness of naturally moist mucous membranes, for example, ocular surface, oral, vaginal, nasal mucous membranes, tissues in contact with biological fluids such as synovial, cephalospinal, peritoneal, pericardial fluids, bone marrow, joint tissues, epithelia, for example, bladder, lymphatic system, spinal cord. Furthermore, it has been demonstrated, particularly in the examples, that the composition according to the invention allows for the treatment and / or improvement of mucosal hydration in a tissue or organ. In particular, a person of ordinary skill in the art, in light of the following examples in which a wide variety of tissues and organs are effectively treated, readily understands and can, based on this knowledge, extrapolate to other tissues and organs that can be treated by the present invention. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of dryness of the mucous membranes, for example, of the vaginal mucosa, of the oral mucosa. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of dry eye. It has also been surprisingly shown that the composition according to the invention advantageously allows the treatment of fibrosis of biological tissues; in particular, it has been shown that the composition according to the invention surprisingly allows a reduction of fibrosis, in particular a synergistic decrease in the synthesis ratio of collagen 3 and collagen 1 (COL3 / COL1), fibrosis being characterized, among other things, by an overexpression of COL3 with respect to COL1). Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of fibrosis. Furthermore, it has been demonstrated, particularly in the examples, that the fibrosis amenable to treatment with the composition according to the invention can be any type of fibrosis, regardless of its origin, and can also be any type of fibrosis, tissue, or organ. In particular, those skilled in the art, in light of the following examples where a wide variety of fibrosis are effectively treated, readily understand and can, based on this knowledge, extrapolate to other fibrotic conditions likely to be treated by the present invention. This could include, for example, fibrosis induced by ischemic lesions, such as muscular and / or cardiac ischemic lesions.It may be, for example, scar fibrosis after ischemia or crushing of skeletal muscle, ischemia of infarcted cardiac muscle, fibrosis of tendinous tissues or ligaments, bone tissue, for example, a bone wedge, fibrosis of digestive tissues, for example, in Crohn's disease, post-radiation fibrosis, hepatic fibrosis, pulmonary fibrosis, fibrosis due to Peyronie's disease, post-surgical fibrosis, for example, adhesions of organs or tissues that induce fibrosis, for example, fibrosis after digestive surgery, surgery of tendons, nerves, vessels, natural fibrosis, for example, occurring during glaucoma, for example, fibrosis of the Schlemm's canal, for example, fibrosis occurring during Dupuytren's disease, fibrosis due to carpal tunnel syndrome and / or other tendon fibrosis. According to the invention, hyaluronic acid is as defined above. According to the invention, the biocompatible polymer of formula AaXxYy or AaXxYyZz is as defined above. According to the invention, the pharmaceutical or dermatological composition is as defined above. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the mode and / or route of administration of the biocompatible polymer may be as defined above. It has also been surprisingly demonstrated that the composition according to the invention can be advantageously useful in the treatment of epidermolysis bullosa. In particular, it has been surprisingly and unexpectedly demonstrated that the composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously promotes the healing of ulcers in children suffering from epidermolysis bullosa. It has also been shown, surprisingly and unexpectedly, that the composition according to the invention advantageously promotes the healing of ulcers synergistically and also reduces the pain associated with these ulcers. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of epidermolysis bullosa. According to the invention, hyaluronic acid is as defined above. According to the invention, the biocompatible polymer of formula AaXxYy or AaXxYyZz is as defined above. According to the invention, the pharmaceutical or dermatological composition is as defined above. Advantageously, the composition may be in a form suitable for spraying, for example, by atomization. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the method and / or route of administration of the biocompatible polymer can be as defined above. It can be, for example, a cutaneous application, for example, by spraying, for example, with a sprayer comprising the composition. It has also been surprisingly shown that the composition according to the invention can be advantageously useful in the treatment of periodontal diseases. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of periodontal diseases. As used herein, periodontal disease is understood to mean any periodontal disease known to those experienced in the technique. This could be, for example, gingivitis or periodontitis. It has also been surprisingly shown that the composition according to the invention can be advantageously useful in the treatment of oral mucosal diseases. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of oral mucosal pathologies. In this context, oral mucosal pathologies are defined as any pathology of the oral mucosa known to those experienced in the technique. These may include, for example, aphthous ulcers, gingivitis, and mucositis. It has also been surprisingly demonstrated that the composition according to the invention can be advantageously useful in the treatment of skin burns, whatever their cause. These may include, for example, thermal burns, post-radiation burns, skin burns due to UV exposure, and skin burns due to exposure to ionizing radiation, such as X-rays or gamma rays. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of skin burns. According to the invention, hyaluronic acid is as defined above. According to the invention, the biocompatible polymer of formula AaXxYy or AaXxYyZz is as defined above. Advantageously, the biocompatible polymer of formula AaXxYy or AaXxYyZz can have a molecular weight of 3000 to 150,000 Daltons. According to the invention, the pharmaceutical or dermatological composition is as defined above. Advantageously, the composition may be in a form suitable for atomization, for example, as a spray and / or a gel. Advantageously, the composition may be in a form suitable for atomization, for example, as an aerosol or a gel, and does not contain fatty acids. Advantageously, when the composition is in a form suitable for atomization, for example, a spray and / or a gel, and does not contain fatty acids, it advantageously allows the treatment of burns while avoiding the presence of fatty acid residues, thus preventing any possible undesirable effects. It has also been surprisingly shown that the composition according to the invention can be advantageously useful in the treatment of degenerative diseases. Therefore, an object of the present invention is also a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid according to the invention for use as a medicament for the prevention and / or treatment of degenerative diseases. In the present case, degenerative diseases are understood to mean any degenerative disease known to those experienced in the technique. This may include, for example, sequelae of a stroke, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, retinal degeneration, degenerative diseases linked to tissue degradation, such as joint and / or muscle damage, myopathies, and age-related degenerative diseases. Advantageously, it has been shown that the composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid allows for the recreation of a better cellular microenvironment favorable to the functional survival and recovery of tissues, advantageously allowing for a slowing and / or treatment of degenerative diseases. The present invention also relates to a composition for application as a medicament, the composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid. According to the invention, hyaluronic acid is as defined above. According to the invention, the biocompatible polymer of formula AaXxYy or AaXxYyZz is as defined above. The composition is as defined above. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the mode and / or route of administration of the biocompatible polymer can be as defined above. The present invention also relates to a method for treating a patient comprising, in any order, the following steps: i. administration of at least one biocompatible polymer and ii. administration of hyaluronic acid, wherein the administrations are concomitant, successive or alternative. The biocompatible polymer is as defined above. Hyaluronic acid is as defined above. According to the invention, the patient can be any mammal. It could be, for example, an animal or a human being. According to the invention, the mode and / or route of administration of the biocompatible polymer can be as defined above. According to the invention, the mode and / or route of administration of hyaluronic acid can be as defined above, preferably by injection into biological tissue. According to the invention, the frequency of administration of the biocompatible polymer can be as defined above. According to the invention, the frequency of hyaluronic acid administration can be as defined above. According to the invention, the administration of hyaluronic acid and biocompatible polymers can be simultaneous, for example, in a single mixture or composition, or successively. According to the invention, when hyaluronic acid and biocompatible polymers are administered sequentially, the dosage can be, for example, for each administration, one administration of hyaluronic acid followed by one administration of biocompatible polymers. For example, hyaluronic acid can be administered from 1 minute to 48 hours before the administration of the biocompatible polymers. In other words, even if the present description refers to a composition, it shall be understood that each of the compounds in the composition may be administered concomitantly with the other compounds (e.g., in a single composition or in two compositions, each of these compositions comprising one or more of the components mentioned above, the mode of administration of each of the compounds or composition(s) possibly being identical or different) or independently of each other, e.g., successively, e.g., independent administration of a biocompatible polymer and independent administration of hyaluronic acid, these administrations being carried out in the same patient, concomitantly or successively or alternatively, in an order that is mentioned above or in some other order.These different administrations can be carried out, independently of each other or in a linked way (composition or co-administration), by an identical or different mode of administration (injection, ingestion, topical application, etc.), once or more times a day, week, for one or more successive or non-successive weeks. Advantageously, the invention thus provides a general and simple solution to a complex technical problem for which there is a real and persistent need in the prior art. In particular, it is illustrated in a non-limiting manner by the following examples, which can be easily extrapolated by those skilled in the art to all kinds of conditions, whatever their origin, and to any type of tissue or organ. In particular, the present invention has been shown to be generalizable to all injuries and / or conditions, particularly by virtue of certain common characteristics of the injuries and / or conditions that include an alteration of the extracellular matrix. An object of the present invention is also an ex vivo method for preparing a graft comprising impregnating a graft and / or organ to be grafted in a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid as defined above. The present invention also has for use a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid as defined above for the ex vivo preparation of a graft and / or organ. The biocompatible polymer is as defined above. Hyaluronic acid is as defined above. According to the invention, impregnation can be carried out by any method known to those skilled in the art. It can be, for example, by immersing the organ in a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid as defined above, or by infusing a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid as defined above, or by spraying a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid as defined above. An object of the present invention is also the use of a composition comprising a biocompatible polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid as defined above for the in vitro and / or ex vivo preparation of an implantable biomaterial. For example, in implantable biomaterials, the biocompatible polymer can be added, for instance, by impregnation after the biomaterial has been manufactured, for example, for a tissue or organ. Alternatively, it can be added during the biomaterial's manufacturing process from the outset; for example, the biocompatible polymer with formula AaXxYy or AaXxYyZz and hyaluronic acid, as defined below, can be added in successive layers, similar to 3D printing. In this document, implantable biomaterials mean any implantable biomaterial known to those skilled in the art and / or commercially available. This may include, for example, any type of compatible implantable material, biodegradable, cross-linked or not, and preferably colonizable. Implantable biomaterials may be based on the cross-linking of proteins, such as collagen, fibrin, polysaccharides, such as dextran, chitin, hyaluronic acid, alginate, cellulose and their derivatives, biodegradable and biocompatible copolymers based on glycolic, lactic, or malic acids, or polymers that can undergo liquid-gel transitions through temperature-controlled polymerization, or polymerization by enzymes, irradiation, or other methods. Examples include polymers based on polycaprolactone, polyurethane, polytetrafluoroethylene, silicone, or inorganic salts, such as calcium phosphates or hydroxyapatites.This could be, for example, base materials or ceramics, metals such as aluminum, steel, titanium, and / or alloys thereof. Advantageously, when the material is a ceramic and / or metal-based material, impregnation allows for coating the outer surface of the material; impregnation can be advantageously carried out by atomization. According to the invention, the impregnation composition may comprise a concentration of 0.1 pg / ml to 1 mg / ml of biocompatible polymer as defined above. According to the invention, the impregnation composition may comprise a concentration of 0.5 mg.mL-1 to 20 mg.mL-1 of hyaluronic acid as defined above. According to the invention, the impregnation time can range from 5 minutes to 24 hours. Advantageously, the duration of impregnation can depend on the structure of the graft and / or the organ and / or the implantable material. Advantageously, impregnation also improves graft efficacy. In fact, it has been surprisingly demonstrated that the presence of the polymer and hyaluronic acid in the graft and / or organ preservation solution provides a synergistic protective and anti-apoptotic effect. Advantageously, it has been surprisingly demonstrated that the composition according to the invention allows for a synergistic effect, particularly due to the duration of the combination of regenerative and protective properties of MA / a / ZUZI / UUOO I z biocompatible polymers of general formula AaXxYy or AaXxYyZz, also called RGTA and the moisturizing and mechanical properties of native or modified hyaluronic acid. Furthermore, it has been shown that the composition according to the invention advantageously allows for the prevention and / or treatment of defects and / or deterioration linked to sequelae and stresses of all kinds (mechanical, oxidative, irradiative, etc.) and to the aging of tissues and organs of all origins in vitro, ex vivo and in vivo in humans and animals. As has been demonstrated, the composition according to the invention can be used for the prevention, slowing down and improvement of marks linked to tissue aging, particularly those of the skin, for example, the prevention, slowing down and improvement of wrinkles, dark circles, loss of elasticity and flexibility or tension, due to the presence of marks, skin dryness, thickness and / or pigmentation of the skin. As demonstrated, the composition according to the invention can be used for the prevention, slowing and / or treatment of joint pathologies, for example, deterioration of cartilage or synovial tissues. As demonstrated, the composition according to the invention may be useful for the prevention, slowing down and / or treatment of the deterioration of the quality of the epithelium and / or corneal stroma and / or vitreous humor. As demonstrated, the composition according to the invention may be useful for the prevention, slowing and / or treatment of the deterioration of the quality of the bladder epithelium and / or stroma. As demonstrated, the composition according to the invention may be useful for the prevention, slowing down and / or treatment of any tissues and / or biological fluids in which hyaluronic acid is naturally present and / or whose production by cells and / or underlying tissues may be altered and / or the quality and / or stability of hyaluronic acid may be altered. As demonstrated, the composition according to the invention allows advantageously and surprisingly a synergistic recovery of the aesthetic and functional quality of the skin as a whole, but also with other tissues and results in a rejuvenating and functional recovery effect that each of the products individually could not obtain and also an unexpected lasting effect. Furthermore, as demonstrated, it is possible to further improve the prolongation of the effects obtained by a first administration of the composition according to the invention, for example, by repeated delivery, for example, topically, on the epithelium / epidermis / mucous membranes. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows examples of biocompatible polymer structure, for example, the structure of the OTR412, OTR413, and OTR415 compound families. Those experienced in the technique may still notice other advantages when reading the following examples, illustrated by the attached figures, given as an illustration. DETAILED DESCRIPTION OF THE INVENTION Examples In the following examples, different biocompatible polymers, also called RGTAs, were used. Table 2 below summarizes the various biocompatible polymers used in these examples. Table 2: Summaries of different biocompatible polymers (RGTA) used in these examples Biocompatible Polymer No. of Examples RGTA Name Average PM + / -15% CMDS OTR41201 3000 1,2,6 CMDS OTR41202 6000 1,2,6,12 CMDS OTR41203 10000 1,6,8,10 Biocompatible Polymer Number of Examples RGTA Name Average PM + / -15% CMDS OTR41205 20,000 1 CMDS OTR41210 40,000 1 CMDS OTR4120 80,000 1,2,3,5,7,8,9,11,12,13,14,15,16,17 CMDS OTR4122 220,000 1,11 CMDS OTR4125 500,000 1,11 CMDSA OTR41301 3,000 1,6 CMDSA OTR41302 6,000 1,6,8,10 CMDSA OTR41303 10,000 1,6 CMDSA OTR41305 20,000 1 CMDSA OTR41310 40 000 1 CMDSA OTR4131 80 000 1,2,4,5,11,13,14,15,16,17 CMDSA OTR4132 220 000 1.11 CMDSA OTR4135 500 000 1.11 CMDSP OTR415 (F6) 5000 18 Example 1: Preparation of RGTA - stability test of hyaluronic acid in the presence of RGTA and hyaluronidase. The synthesis of RGTAs is widely described in the prior art, for example, in United States Patent No. 7,396,923 entitled Method of sulfonation of compounds comprising free hydroxyl (OH) groups or primary or secondary amines and also in the bibliographic reference Yasunori I. et al., Biomaterials 2011, 32: 769-776) and Petit E. et al., Biomacromolecules. 2004 March-April; 5 (2): 445-52.

[17] : In the following examples, several known and described RGTAs were used, including OTR4120, which is described in numerous preclinical and clinical publications (RGTA-based matrix therapy®: A new branch of regenerative medicine in locomotion. Barritault D, Desgranges P, Meddahi-Pellé A, Denoix JM, Saffar JL. Joint Bone Spine. 2017 May; 84(3): 283-292. doi: 10.1016 / j.jbspin.2016.06.012

[18] , RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Barritault D, Gilbert-Sirieix M, Rice KL, Siñeriz F, Papy-Garcia D, Baudouin C, Desgranges P, Zakine G, Saffar JL, van Neck J. Glycoconj J. June 2017; 34(3): 325-338. doi: 10.1007 / sl0719-016-9744-5

[14] . Compound OTR4131 is a compound comprising a Z radical that is a fatty acid, namely acetic acid as described in Frescaline G. et al., Tissue Eng Part A. July 2013; 19 (13-14) : 1641-53. doi: 10.1089 / ten.TEA.2012.0377)

[19] , Randomized controlled trial demonstrates the benefit of RGTA®-based matrix therapy for the treatment of tendinopathies in racehorses. Jacquet-Guibon S, Dupays AG, Coudry V, Crevier-Denoix N, Leroy S, Siñeriz F, Chiappini F, Barritault D, Denoix JM. PLoS One. March 9, 2018; 13(3): e0191796. doi: 10.1371 / journal.pone.0191796

[20] . Other compounds are also described in patent documents US06689741, US2014301972A1 in which Z is an amino acid such as phenylalanine (heparan sulfate proteoglycans IVIA / a / ZUZΊ / UUOO I ¿ mediate the internalization and propagation of specific proteopathic seeds. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI. Proc Nati Acad Sci USA. August 13, 2013; 110(33): E3138-47. doi: 10.1073 / pnas.1301440110

[21] ) or another hydrophobic compound (Structure-activity studies of heparan mimetic polyanions for antiprion therapies. Ouidja MO, Petit E, Kerros ME, Ikeda Y, Morin C, Carpentier G, Barritault D, Brugére-Picoux J, Deslys JP, Adjou K, Papy-Garcia D. Biochem Biophys Res Commun. November 9, 2007; 363 (1): 95-100

[22] ). The different RGTAs are listed and described in Table 1 with their characteristics, and Table 2 specifies the example numbers in which these compounds were used. In the following example, different RGTAs were tested to determine their effect on hyaluronic acid and, in particular, to determine a possible protective effect of hyaluronic acid against hyaluronidase according to the method described in multiple articles, for example, In vitro evaluation of the sensitivity of a cross-linked hyaluronic acid PEG to bovine testis hyaluronidase Nicola Zerbinati et al. Open Access Maced J Med Sci. 2018 Jan 25; 6(1): 20-24 https: / / doi.org / 10.3889 / oamjms.2018

[23] , Salí I, Férard G. Comparison of the sensitivity of 11 cross-linked hyaluronic acid gels to bovine testis hyaluronidase. PolymDegrad Stab. 2007; 92: 915-919. https: / / doi.org / 10.1016 / j.polymdegradstab.2006.11.020. In this example, type 1-S hyaluronidase (EC 3.2.1.35) was obtained from bovine testis (sigma Aldrich H3506) and diluted in phosphate-buffered saline (PBS) at pH 7.2 to obtain a solution of 5000 U / mL. 0.3 ml of a 20 mg / mL hyaluronic acid gel from strotococcus zooepidemicus (sigma Aldrich H39390) has been deposited at the bottom of 5 ml tubes and 25 pL of RGTA at different concentrations is added, then incubated at 37°C overnight. 125 pL of the enzyme solution were added to the surface of the gel and the tubes were incubated for 2 days (h). The reaction was stopped by adding 0.1 mL of 0.8 mol / L potassium tetraborate solution, pH 9.1, followed by vortexing and then heating for 3 minutes at 100°C. The measurement of enzyme activity by the release of N-acetyl-D-glucosamine (NAG) was carried out using the method of Reissig et al. (Reissig JL, Strominger JL, Leloir LE. A modified colorimetric method for estimating N-acetylamino sugars J Biol Chem 1955; 217: 959e96

[25] . Briefly, a solution of Ehrlich's reagent (Sigma Aldrich) diluted 1 / 10 in acetic acid is added to each tube (3 mL), which are then, after shaking and vortexing, incubated at 37° for 20 minutes, then the tubes are centrifuged at 1000 g for 15 minutes and the supernatant is measured at 585 nm against PBS + Ehrlich reagent. Table 3 below summarizes the results obtained for a constant unmodified amount of hyaluronic acid (300 pL to 20 mg / mL) (MW of 250,000 Daltons) in the presence of 125 pL of hyaluronidase and increasing dose of compound from two RGTA families of different molecular weight sizes ranging from 3000 D to 500000 D described in Table 1. Table 3: Results of hyaluronic acid degradation in the presence of biocompatible polymers and hyaluronidase HA in modified RGTA: 25pL RGTA OTR (pg / mL) RGTA 4120 41201 41202 41203 41205 41210 4122 4125 % degradation of HA by hyaluronidasa + / - 5% 300pL 50 5% 4% 5% 5% 5% (5%) 100% 100% RGTA 4131 41301 41302 41303 41305 41310 43132 4135 300pL 50 3% 5% 5% 5% 5% 5% 5% 5% gel 10 4% 8% 7% 6% 5% 5% 5% 5% HA 1 38% 45% 44% 44% 42% 40% 40% 40% 20 mg / mL) 0 100% 100% 100% 100% 100% 100% 100% 100% Leyenda de Tabla 3: 300 pL of gel + 25 pL RGTA + 100 pL (800U) Enzyme incubated for 2 days at 37°C. Stop with 0.1 ml of potassium tetraborate (0.8 mol / L, pH 9.1). Mix with vertex, heat for 3 min at 100° C and add 3 ml of Ehrlich reagent and read at 585 nM. As shown in Table 3 above, RGTA has an inhibitory effect on hyaluronidase activity and / or a protective effect on hyaluronic acid. This example also clearly demonstrates that the effect is dose-dependent. A 25 pL dose of RGTA at 10 pg / mL is as effective as a 50 pg / mL dose. This example also clearly and advantageously demonstrates that a low concentration (1 pg / mL of biocompatible polymer (RGTA)) advantageously allows for more than 60% inhibition of hyaluronic acid degradation by hyaluronidase.This example also shows that there is no difference in the protective effect of RGTAs against hyaluronidase degradation according to the molecular weight of the RGTAs, nor between carboxylmethyl dextran sulfate RGTA, namely OTR41201, OTR41202, OTR41203, CMDS OTR41205, CMDS OTR41210, CMDS OTR4120, CMDS OTR4122, CMDS OTR4125, or carboxylmethyl dextran sulfate RGTA, namely OTR41301, CMDSA OTR41302, CMDSA OTR41303, CMDSA OTR41305, CMDSA OTR41310, CMDSA OTR4134 OTR4131, CMDSA OTR4132, CDMSA OTR4135 described above in Table 1. Example 2: Effect synergistic effect of RGTA and AH on collagen synthesis, on the reduction of the fibrotic index and on the polarity of collagen secretion. RGTAs are also known to modulate collagen expression and fibrosis (US06689741, US2014301972A1 [4]) in the skin; many articles describe these properties, particularly in the treatment of cutaneous fibrosis (Garcia-Filipe et al. 2007 [8]), muscle tissue (A substituted dextran improves the survival and regeneration of muscle fibers in ischemic and denervated rat EDL muscle. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. FASEB J. April 1999; 13 (6): 761-6

[26] ), and cardiac tissue (New agents for the treatment of infarcted myocardium. Yamauchi H, Desgranges P, Lecerf L, Papy-Garcia D, Tournaire MC, Moczar M, Loisance D, Barritault D. FASEB J. November 1999). 2000; 14 (14): 2133-4), bone (Barritault et al. 2017

[18] ) or digestive (Alexakis et al., 2004 [5]). However, the effect of a possible combination of RGTA with AH has not been studied or is known. Human dermal fibroblasts were cultured in 24-hole plate wells according to the protocols described by Garcia-Filipe S et al. 2007 [8]. Fibroblasts inoculated at 10,000 cells per well are cultured for 5 days to reach confluence with 90,000 cells per well, then placed in a serum-free medium for 24 hours in the presence of 15 mCi / mL of 5-3H Proline and 50 mg / mL of ascorbic acid in the presence or absence of RGTA OTR4120 or OTR4131 at 10 and 100 pg / mL and HA (20 mg / ml) according to the following protocol. The culture medium and cells are collected separately after 24 hours, dialyzed against water, digested with pepsin, and collagen phenotypes are analyzed after separation by SDS gel electrophoresis according to the method described in Asselot-Chapel C et al. Fibronectin and interstitial collagen gene expression in smooth muscle cells: modulation by low molecular weight heparin fragments and serum. Biochem Pharmacol. March 1, 1995; 49(5): 653-9

[28] . The areas corresponding to collagens 1 and 3 were cut from the gel and the tritium was counted. The percentage of total cellular collagen is the ratio between the radioactivity in the cell layer and the radioactivity in the supernatant. Table 4 below summarizes the results obtained Table 4 RGTA RGTA 100pg / mL AH 20mg / mL COL3: dpm 3H / 1000 cells (+ / -10%) COL1 dpm 3H / 1000 cells (+ / -10%) COL3 / COL1* % total cellular COL - - 170 720 0.23 7 - + 170 960 0.177 7 RGTA RGTA 100pg / mL AH 20mg / mL COL3: dpm 3H / 1000 cells (+ / -10%) COL1 dpm 3H / 1000 cells (+ / -10%) COL3 / COL1* % total cellular COL Heparin 4- 100 600 0.166 15 CMDS OTR4120 4- - 60 720 0.083 30 CMDS OTR4120 4- 4- 60 1100 0.054 45 CMDS OTR4120 1 4- - 45 720 0.062 8 CMDS OTR4120 1 4 4- 45 1100 0.041 35 CMDS OTR4120 2 4- - 45 720 0.062 6 CMDS OTR4120 2 4· 4- 45 1100 0.041 35 CMDSA OTR4131 4- - 60 730 0.082 30 CMDSA OTR4131 4- 4- 60 1180 0.050 45 * A measurement in normal mouse skin using comparable techniques gives a COL1 to COL3 ratio of 10 (Figure 1 from Garcia-Filipe S et al., 2007 [8]). As shown in Table 4 above, RGTAs have an effect on the regulation of collagen synthesis by decreasing the amount of collagen 3 by almost 3 times (from 170 to 60, resulting in in vivo a reduction of fibrosis) also as an effect of AH in a 20% increase (720 vs 960) in collagen 1 synthesis. As shown in Table 4 below, the combination of polymer and hyaluronic acid unexpectedly has a synergistic effect for COL1 synthesis with a 40% increase (720 to 1100). As shown in Table 4 below, the combination of polymer and hyaluronic acid also unexpectedly has a synergistic effect on the polarization of collagen secretion at the cellular and matrix levels. The percentage of collagen increases from 7% to 45%, or 6.4 times more, compared to all the total collagen accumulated in the cellular and pericellular space. As demonstrated in this example, the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously and synergistically allows an increase in collagen synthesis, an improvement in collagen synthesis and advantageously allows the recreation of the matrix space favorable to good cell and tissue differentiation. Example 3: Synergistic effect of RGTA and AH in ex vivo use in tympanic membranes, corneas and biomaterials and in 3D printing methods of tissues or organs. 3-1 Pre-incubation of tympanic membranes and corneas before organ transplantation / preservation. In this example, OTR4120 at 10 μg / mL was used in a 5 mg / mL solution of commercially available injectable hyaluronic acid (HA), sourced from various suppliers, to impregnate the graft, such as the cornea or tympanic membrane, for a few minutes. The impregnation is performed before the transplant, and then a few drops of the same solution are added at the end of the procedure. In the surgeons' opinion, the grip and functional recovery were of much better quality than that observed according to previous protocols. 3-2 Pre-incubation of biomaterials for bone or cartilage filling with the product of the invention. In this example, several bone substitute biomaterials used for bone, cartilage or intervertebral disc reconstruction were impregnated with a solution comprising the combination according to the invention, namely, a polymer combination of formula AaXxYy or AaXxYyZz and AH before being implanted. In this example, the useful impregnation solution comprises OTR4120 at a concentration of 10 pg / mL and a hyaluronic acid concentration of 1 mg / mL. Impregnated biomaterials are decellularized bone powders or synthetic products such as ceramics, in particular tricalcium phosphate or TCP or hydroxyapatite AH, or composite biomaterials that further comprise proteins such as collagen. 3-3. Use of a composition comprising a polymer combination of formula AaXxYy or AaXxYyZz and hyaluronic acid (HA) as ink in 3D printing methods of tissues or organs. In this example, the useful composition comprises a concentration of 10 to 100 pg / mL and a hyaluronic acid concentration of 1 to 20 mg / mL according to the printing methods or processes described in several reviews, in particular Jammed Microgel Inks for 3D Printing Applications. Highley CB, Song KH, Daly AC, Burdick JA. Adv Sci (Weinh). October 24, 2018; 6(1): 1801076. doi: 10.1002 / advs.20180107 6.

[33] . Collagen / heparin sulfate scaffolds fabricated by a 3D bioprinter improved mechanical properties and neurological function after spinal cord injury in rats. Chen C, Zhao ML, Zhang RK, Lu G, Zhao CY, Fu F, Sun HT, Zhang S, Tu Y, Li XH. J Biomed Mater Res A. May 2017; 105 (5): 1324-1332. doi: 10.1002 / jbm.a.36011.

[34] Development and evaluation of hyaluronic acid-based hybrid bioink for tissue regeneration. Lee J, Lee SH, Kim BS, Cho YS, Park Y. Tissue Eng Regen Med. 2018 Sep 21; 15 (6): 761-769. doi: 10.1007 / sl3770-018-0144-8.

[35] . As demonstrated in the previous example, it is clear that the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid allows for a synergistic effect, particularly in vitro, advantageously enabling the recreation of the matrix space conducive to good cell and tissue differentiation. Furthermore, this example clearly demonstrates that this effect can be achieved for all applications and / or tissues requiring the production, reformation, and / or augmentation of the extracellular matrix. This example also clearly demonstrates, in particular by stimulating the production of extracellular matrix components, that the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid also advantageously allows the protection of hyaluronic acid from degradation and further prolongs the effects of HA in its tissue filling and hydration uses. It is also clear that the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid allows an improvement in the organization, distribution, and polarization of the production of matrix constituents such as collagens, advantageously allowing an improvement in the quality of the extracellular matrix and the treated tissue in general, whatever the tissues or organs considered. It is also clear that the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid allows, during an injury or micro-injury of a biological tissue, a replacement of both heparan sulfates and hyaluronic acid destroyed during the injury by respectively the polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid present in the composition according to the invention. Furthermore, during the injection of the composition according to the invention, potential destruction of the matrix space may occur at the site of penetration of the composition and subsequently spread through diffusion of the injected composition, causing microlesions associated with filling the space. These microlesions can induce a local inflammatory reaction and destruction of the microenvironment and matrix architecture. The polymer of formula AaXxYy or AaXxYyZz can then replace endogenous heparan sulfates, whose destruction can be triggered in response to this tissue attack by the inflammatory response of the tissue, thus aiding in the reconstruction of the matrix architecture while the hyaluronic acid fills the microenvironment space.Injury-induced glycanases can be activated, but advantageously inhibited by the polymer of formula AaXxYy or AaXxYyZz, thus allowing for a reduction and prolonged duration of tissue filling. Furthermore, as demonstrated, the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid, which has an unexpected synergistic effect on dermal fibroblast cells, advantageously allows for increased synthesis and quantity of Collagen 1 (COL1) and reinforcement of the tissue matrix, regardless of the tissue type. Therefore, this example clearly demonstrates that the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allows for a reinforcement of the skin barrier function, enabling an improvement in the quality and appearance of the skin, particularly by enhancing its hydration, thickness, and flexibility. Furthermore, this example also clearly demonstrates that the effect is long-lasting, particularly through the inhibition of enzymes responsible for collagen degradation, but also through the induction / stimulation of collagen synthesis. Furthermore, this example also clearly demonstrates that a composition comprising a polymer with the formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allows for the creation of a higher-quality extracellular matrix, which in turn will indirectly induce a higher-quality cellular response. This feedback loop effect will prolong the beneficial duration of the treatment and its anti-aging effect. Example 4: Use of a composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid for the treatment of skin aging In this example, cosmetic compositions comprising RGTA OTR4131 and hyaluronic acid were used topically. Specifically, a day cream named FOR075.039 containing 1 pg / ml of RGTA OTR4131 with 20 mg / ml of hyaluronic acid (MW-400 to 700 kD), a night cream named FOR075.040 containing 1 pg / ml of RGTA OTR4131 with 20 mg / mL of hyaluronic acid (MW-400 to 700 kD), and a serum named FOR075.041 containing 2 pg / mL of RGTA OTR4131 with 40 mg / mL of hyaluronic acid (MW-400 to 700 kD) were used. The hyaluronic acid is from Biphil (http: / / www.biophilgroup.com / ). Tables 5 to 7 summarize the characteristics of the compositions used; the biocompatible polymer of formula AaXxYyZz used is designated as carboxymethyl dextran acetate sodium sulfate in these tables: Table 5: Day cream formulation INCI EU name % (m / m) θη the product Water 66.6899 Caprylic / capric triglyceride 8.5000 Glycerin 8.5000 Pentylene glycol 5.0000 Coco-caprylate 3.4984 Coco alkanes 2.8000 Hydroxyethyl acrylate / acryloyldimethyl taurate copolymer sodium 1.7000 Acrylates copolymer 1.4100 Coconut caprylate / caprate 0.7000 Perfume 0.5000 Ethylhexylglycerin 0.3000 Sodium hyaluronate 0.2000 Sorbitan isostearate 0.1100 VP / Polycarbamyl polyglycol ester 0.0500 pg-propyl hydrolyzed sesame protein Methylsilandiol 0.0400 Tocopherol 0.0016 Carboxymethyl dextran acetate sodium sulfate 0.0001 Table 6: Night cream formulation INCI Name EU % (m / m) in the product Water 53.4999 Helianthus annuus seed oil 10.0000 Octyldodecyl myristate 8.0000 Coco alkanes 6.4000 Glycerin 5.0000 Pentylene glycol 5.0000 Glyceryl citrate stearate 4.0000 Zea mays starch 2.5000 Glyceryl stearate 2.0000 Coconut caprylate / caprate 1.6000 Tocopheryl acetate 1.0000 Ethylhexylglycerin 0.3000 Xanthan gum 0.3000 Perfume 0.2000 Sodium hyaluronate 0.2000 Sodium carboxymethyl dextran acetate sulfate 0.0001 Table 7: Serum formulation Name inCI EU % (m / m) in the product Water 82.1598 Glycerin 6.4000 Pentylene glycol 5.0000 Caprylic / capric triglyceride 2.0000 Helianthus annuus seed oil 2.0000 Sodium acrylates copolymer 0.7000 Polyglyceryl-3 methyl glucose distearate 0.5000 Sodium hyaluronate 0.4000 Lecithin 0.3000 Ethylhexylglycerin 0.3000 Parfum 0.2000 Terminalia ferdinandiana fruit extract 0.0400 Sodium carboxymethyl dextran acetate sulfate 0.0002 This study was carried out in a target population of women with a mean age of 62 ± 1 years (47 and 67 years) and whose skin type and phototype were distributed as follows: 50% had mixed skin, 9% normal and 43% dry divided into two phototypes: type 2 for 59% and type 3 for 41%. The application and frequency of application are described in Table 8 below. The analysis of the results is MA / a / ZUZI / UUOO I z was performed using the 3D Primo System (registered trademark) Lite, the Conometer (registered trademark), DUB (registered trademark) Skin Scanner Conometer (registered trademark) and clinical scores from questionnaires, received randomly. Table 8: Protocol for application and use of the compositions Areas Frequency Method Daytime FOR075.039 At home: face and décolleté. In the laboratory: defined treatment area at leg level (based on only 11 volunteers). At home: once a day (morning) before makeup, after bathing and serum application. In the laboratory: a single standard application (2 µL / cm²) in synergy with two other products. At home: apply to the face with a light massage until fully absorbed. In the laboratory: light, even massage with one finger. Nighttime - FOR075.040 At home: once a day (evening) after bathing. In the laboratory: a single standard application (2 µL / cm²) in synergy with two other products. Serum - FOR075.041 At home: once a day (morning) after bathing and before night cream. In the laboratory: a single standard application (2 µL / cm²) in synergy with two other products.At home: Apply to the face with a light massage until fully absorbed, paying special attention to areas with wrinkles and freckles. In the laboratory: Massage lightly and evenly with one finger. In this example, the following effects of the compositions were studied: Anti-aging effect; Softening effect; Detoxifying effect; Effect on skin firmness, elasticity and flexibility; Redensifying / volumizing effect; Hydrating effect. In particular, an evaluation of the following parameters was carried out: Smoothing / anti-wrinkle effect of the products studied by measurements with the Primos® 3D system Lite; its detoxifying effect by clinical scoring performed by the technician in charge of the study; its effect on the biomechanical properties of the skin through measurements with the Cutometer®; its redensifying effect by measuring the density of the dermis with the DUB® SkinScanner; Its moisturizing effect two and four hours after a single standardized laboratory application using measurements with Cornéométre® (only affects 11 volunteers); Making and collecting skin impressions in Silflo® polymeric silicone replicas subjectively assessing their cosmetic acceptability, efficiency and subsequent use by analyzing the responses given by volunteers to a subjective evaluation questionnaire. compilation of undesirable reactions. The results obtained are summarized in Tables 9 to 13 below: iviA / a / ¿u¿ i / uuoo i ¿ IT OR IT IVIA / d / ZUZ I / UUOO I z % of volunteers showing improvement 100% 100% % of efficacy 80% 90% Statistics Significance ¿o U3 II Q. <0.001 <0.001 ΔΔ Tx-TO (average + / SEM) 17 ± 1 20 ± 1 Kinetics £ CM < Δ t4h Parameter Degree of skin hydration iviA / a / ¿u¿ i / uuoo i ¿ Table 13: Summary of results obtained Parameters Results Skin Hydration - T2H: Average improvement in 80% of 100 users. - T4H: Average improvement in 90% of 100 users. Anti-Wrinkle J28: Average 3% reduction in skin texture and roughness in 68% of users. Brightness and Luminosity - J7: Average 23% improvement in 86% of users. J28: Average 42% improvement in 100% of users. Skin Tones Uniformity J28: Average 34% improvement in 86% of users. Skin Texture J28: Average 38% improvement in 86% of users. Skin Freshness - J7: Average 27% improvement in 91% of users. - J28: Average 47% improvement in 95% of users. Elasticity J28: Average improvement of 47% in 91% of patients. Tone J28: Average improvement of 39% in 73% of users. As demonstrated in the tables above, examples of compositions according to the invention have advantageously enabled increased skin hydration, with an anti-wrinkle effect, improved skin radiance and luminosity, and uniformity of complexion, skin texture, skin freshness, elasticity, and skin tone. Table 14 below includes the results obtained and demonstrates the effectiveness of the composition used. Table 14 Properties Favorable Overall Appreciation Pleasant to use 100% Pleasant appearance 100% Absorbs quickly 100% Fragrance appreciation 91% Leaves skin non-greasy 100% Leaves skin non-greasy and non-sticky 96% User's perceived effectiveness Leaves skin soft 100% Makes skin supple 100% Nourishes and moisturizes skin 100% Regenerates skin 96% Smoothes wrinkles and fine lines 95% Has a firming effect 96% Revives complexion radiance 95% Improves skin texture 96% My acquaintances find me younger 86% No adverse reactions were observed during the study, and the majority of volunteers appreciated the formulas for their characteristics and effectiveness. In fact, over 95% of the subjects wished to continue using the tested formulas. As previously demonstrated, examples of compositions according to the invention have advantageously enabled synergistically increasing skin hydration, with an anti-wrinkle effect, improving skin radiance and luminosity, evenness of complexion, skin texture, skin freshness, elasticity, and skin tone. Furthermore, this example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously improve the appearance of the skin, have an anti-aging effect on the skin, particularly an anti-wrinkle effect, and smooth the skin. Moreover, this example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously detoxify the skin by increasing and improving its mechanical properties, such as elasticity and flexibility. Furthermore, this example clearly demonstrates that examples of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for improved skin hydration. Example 5: Effect on wrinkle filling by intradermal or subcutaneous injection of the RGTA and HA mixture The use of RGTA 4120 or OTR 4131 by subcutaneous injection and HA injection for wrinkle reduction and during the duration of this effect has been carried out by physicians and / or patients. The administrations were carried out on the sole initiative of the physicians or patients for themselves and by themselves (the patient may be a physician) or by myself using commercially available sterile OTR4120 or OTR4131 based products and AH also available (according to country via the Internet or other) sometimes from samples originally intended for research. In all cases these uses were off-label, both RGTA products and AH from different sources were administered in combinations and according to the different procedures indicated and the effects are summarized below. Sometimes, patients themselves have used several different formulations and operating methods on different areas of wrinkles (in particular, crow's feet, forehead wrinkles, Leo wrinkles, perioral wrinkles, nasolabial folds, lip furrows, bags under the eyes, neck wrinkles, etc.). The administration methods were independently as follows: Co-injection of a mixture of hyaluronic acid HA and RGTA OTR4120 or 4131 was performed in the syringe before injection (which can be repeated after 1 month) or AH injection followed by injection after 24 or 48 hours of the RGTA (OTR4120 or 4131) and AH mixture. The RGTA OTR 4120 or OTR 4131 in sterile solution in physiological saline respectively at 100 pg / mL (in 5 mL vials) and 10 pg / mL (in 1 mL vials). The injected volumes of RGTA alone do not exceed 1 ml per injection site. The injection method is carried out with insulin-type needles or mesotherapy. Hyaluronic acid or HA comes from different natural sources, is of different sizes or cross-linked, and is freely available on the market depending on the country (through websites, in pharmacies, or through distribution networks with doctors). AH is in solution between 0.5 and 25 mg / mL, preferably between 10 and 20 mg / mL. The effect on wrinkles is evaluated according to the satisfaction of the treated individual. In all cases, improvement is observed within 15 days, with a visible effect and the disappearance of signs of inflammation (redness, pain) associated with the injection process. This rapid effect is also remarkable, especially the quick disappearance of the signs of inflammation. The effects are confirmed after one month, and also after six months, with good satisfaction across all treatments. This sustained effect is unusual and is observed even with high molecular weight, non-crosslinked natural hyaluronic acid. Therefore, this example clearly demonstrates that an example of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously improves the appearance of the skin and can be useful for filling wrinkles and / or expression lines. Furthermore, this example clearly demonstrates that an example of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously provides a rapid effect without undesirable side effects, while limiting any potential inflammatory reaction. This example clearly demonstrates that an example of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allows for improving the appearance of the skin and can be useful for filling wrinkles and / or fine lines without requiring multiple and / or repeated applications of the composition. 100 Finally, this example clearly demonstrates that an example of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allows for improving the appearance of the skin and can be useful for filling wrinkles and / or fine lines in a lasting manner, for example, for 6 months after application. Example 6: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid against skin aging. In this example, compositions for topical application are prepared. This is a topical formulation comprising OTR41201 or OTR41202 or OTR41203 or from the OTR413101, OTR413102, or OTR413103 family at doses of 0.11, 10, or 100 pg / mL of final product. In particular, compositions for topical application are prepared composed of OTR41201 or OTR41202 at doses of 1 to 10 pg / mL with or without hyaluronic acid in concentrations ranging from 0.1 mg / mL (preferably 10 mg / mL) to 20 mg / mL (preferably 20 mg / mL). The cream formulations correspond to those used in Example 4. These compositions are useful as a single application but also in addition to the application and / or treatment of wrinkle fillers with a composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid as described in Example 5 above. In this example, after filling in the wrinkles as shown 101 described in Example 5 above, the aforementioned topical composition comprising OTR41201 or OTR412002 at doses of 0.1, 1, 10 or 100 pg / mL of final product is prepared, in particular, compositions for topical application comprising OTR41201 or OTR412002 at doses of 1 to 10 pg / mL with hyaluronic acid at concentrations of 0.1 mg / mL, preferably 20 mg / mL is applied to the area of ​​skin that has been previously treated. Advantageously, the polymer with the formula AaXxYy or AaXxYyZz used, namely OTR41201 or OTR41202, has a low molecular weight that allows it to cross the epidermal barrier and penetrate the dermis, reinforcing the local effect of the previously administered composition. For example, it advantageously allows for a further increase in collagen secretion and polarity, as well as increased protection of hyaluronic acid (HA) against glycanase degradation, and maintains and / or further prolongs the beneficial effect of RGTA and HA on the cellular microenvironment. Furthermore, this example clearly demonstrates that compositional examples according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for improving the appearance of the skin, particularly due to an increase in collagen secretion and polarity, but also to increase the protection of HA against the 102 degradation by glycanases. Furthermore, this example clearly demonstrates that compositional examples according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for a long-lasting effect and / or further prolong the favorable synergistic effect of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the cellular microenvironment. Example 7: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the treatment of vaginal dryness by injection In this example, the composition used is the one described in Example 5 above, comprising 10 pg / mL of OTR4120 and 20 mg / mL of HA from different sources in physiological saline solution. The mixture is prepared by drawing 100 pL of an OTR4120 solution into a syringe. After connecting this syringe with an adapter to the syringe containing the HA solution to be injected, the contents are transferred from one syringe to the other. In the case of small injections, namely 100 pl of the composition, very superficial injections of the product of the invention were made into the mucous membranes of the area between the vagina and the opening of the labia minora. These were distributed at approximately ten sites around the circumference of the vagina, just behind the opening. The injection sites were then massaged to distribute the product evenly. A comparison of the filling effect and / or 103 Tissue hydration between the composition comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid compared to a conventional composition comprising only hyaluronic acid. According to the physician, the effect obtained with an example of a composition according to the invention, namely comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid, was considered better over time than treatment with a composition comprising only hyaluronic acid. This example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously enable the treatment and / or improvement of vaginal dryness. In particular, this example clearly demonstrates that the compositions according to the invention enable the hydration of biological tissues, particularly mucous membranes, and specifically the vaginal mucosa. Example 8: Use of AaXxYy or AaXxYyZz formula polymers and hyaluronic acid for the treatment of vaginal dryness In this example, the composition used is the one described in Example 7 above, namely, a composition containing 10 pg / mL of OTR4120 and 20 mg / mL of HA from different sources in physiological saline solution. The gel is placed on the finger and massaged into the vaginal mucosa. This treatment can be performed a few weeks after the 104 injection performed in accordance with Example 7. It has also been reported that the use of a gel made with OTR41203 is very effective. This example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously enable the treatment and / or improvement of vaginal dryness. In particular, this example clearly demonstrates that the compositions according to the invention, particularly when applied topically, enable the hydration of biological tissues, particularly mucous membranes, and especially the vaginal mucosa. Example 9: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid for the treatment of dry eye. In this example, the composition used corresponds to an eye drop comprising hyaluronic acid where CACICOL (registered trademark) is based on RGTA OTR4120 at 100 pg / mL. Thus, 3 to 4 doses of CACICOL are added, that is, approximately 1.3 mL of OTR4120 at 100 pg / mL or 1 mL of CACIPLIQ (OTR4120 at 100 pg / mL) to 10 mL of a 0.15 g / mL hyaluronic acid solution (for example, in a multidose bottle of the ABAK type from thealose (Théa Laboratories) or Viskyal or Aqualarm. Several patients with severe dry eye (Sjogren's) have been treated with the eye drop mixture comprising hyaluronic acid and a polymer of formula AaXxYy or AaXxYyZz, a IVIA / d / ZUZ I / UUOO I z 105 saber, OTR4120, by administering one drop every 6 hours. Very quickly, the need to add one drop of the mixture at this frequency decreases to 2 and then to 1 drop per day and stabilizes at one drop every two or three days. A reduction in dry eye has been observed, particularly due to a decrease in the patient's need to apply the product and / or a decrease in the frequency and duration of treatment, especially compared to conventional eye drops. This effect is described for CACICOL eye drops (Evaluation of a novel matrix regenerating agent in patients with Sjógren's syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases. Fajnkuchen F, Barritault D, Giocanti-Aurégan A. Medicine (Baltimore). March 2018; 97 (10): e9935. doi: 10.1097 / MD.0000000000009935.

[29] ).However, and surprisingly, the effect is much faster with the combination according to the invention, namely, a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid and also more stable, in particular making it advantageously possible to promote the reconstruction of a more durable tear system, particularly with the continued application of the composition according to the invention. This example clearly demonstrates that examples of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid 106 advantageously allow for the treatment and / or improvement of dry eye. In particular, this example clearly demonstrates that examples of the composition according to the invention, particularly when applied topically, allow for the hydration of biological tissues, particularly the cornea, and advantageously allow for the promotion and / or restoration of the lacrimal system. Example 10: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid for rehydration, preservation of dryness and hair regrowth. In this example, the product used is Laluset cream (Genevrier laboratory (www.laboratoiresgenevrier.com)) which contains a mixture of 0.2% hyaluronic acid in 100 g mixed with 1 mg of OTR41302 in physiological saline. This cream is used every 3 days in a scalp massage. This treatment shows a hair loss prevention effect, which can advantageously stimulate hair regrowth in treated subjects, whereas compositions containing only AH alone or RGTA alone have shown no effects, in particular no perceptible effect. The composition described in Example 8 above is also useful for this application. This example clearly demonstrates that examples of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow the scalp to be rehydrated, while 107 that hydrates the hair fiber. Furthermore, this example clearly demonstrates that examples of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for the prevention of hair loss and / or the stimulation of hair regrowth. Furthermore, this example clearly demonstrates that examples of a composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for the prevention and / or treatment of alopecia. Example 11: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid for the treatment of superficial skin burns (thermal or post-radiation) or lesions induced by desquamation and skin ulcers due to detachment of the epidermis or lesions of the skin or mucous membranes, for example, after an episiotomy. In this example, the compounds used are identical to those described in Example 6 or the one described in Example 10 above. Spray compositions are prepared comprising 0.05 to 1% hyaluronic acid and 10 pg / ml of OTR4132, OTR4135, OTR4120, OTR4122, or OTR4125 in physiological saline solution (or water). These compositions have proven particularly useful and effective for treating superficial burns. Furthermore, the use of the formulation, especially 108 in the form of atomization, avoided pain and the risk of aggravation of the injury that may occur during the application of the composition. Advantageously, this aqueous solution for spray formulation does not contain fatty acids, which avoids the risk of inducing a burn due to the presence of fatty acid residues not yet removed from the cream, which cause a worsening of the burn by a barbecue effect. This formulation has also been shown to be synergistically effective in inducing better healing and reducing pain than any of the products used separately would allow us to observe. Very high molecular weight RGTA-based products, in particular OTR4122, OTR4125, and the forms containing acetylated groups of OTR4132 and OTR4135, when sprayed and mixed with hyaluronic acid, have proven to be even more effective, especially when this spray was used in patients suffering from epidermolysis bullosa, further improving upon the effects described for this condition with OTR4120 alone (A Rapid Response to Matrix Therapy With RGTA in Severe Epidermolysis Bullosa. Malaq AA, Barritault D. Eplasty. 2012; 12: ic!5

[30] ). Furthermore, the use of the combination and / or composition according to the invention advantageously allows for stronger closed wounds and / or wounds that heal more effectively; for example, closed wounds appear more... 109 resistant to reopening. Likewise, pain was significantly reduced during topical application of the product in spray or gel form, as described in the epidermolysis bullosa example, or during episiotomy healing by topical application of the gel (according to example 8) or spray. These examples clearly demonstrate that the compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously promote healing of, for example, skin wounds and / or burns. Furthermore, this example clearly demonstrates that the compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously promote the healing of skin ulcers resulting from epidermolysis bullosa or from injury caused by incision or tearing of mucous membranes, and also advantageously promote long-lasting healing with improved scar quality and reduced pain. Example 12. Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the treatment of mouth ulcers, gingivitis or mucositis In this example, aqueous formulations comprising RGTA OTR4120 or RGTA OTR41202 at 10 pg / ml are prepared. 110 mixed with hyaluronic acid (10 mg / ml). The aqueous solutions are placed separately in 20 mL glass vials sealed with a stopper equipped with a pump that delivers 140 pL / at each pressurization. The composition is atomized directly into the mouths of patients with aphthous ulcers, gingivitis, or mucositis. Thus, the products of the invention, particularly when administered as an atomization, show significantly better efficacy in the treatment of aphthous ulcers, gingivitis, and mucositis, and in particular, the effect on the treatment of aphthous ulcers, gingivitis, and mucositis is faster than that of each of the products taken separately. This example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously enable the treatment of oral wounds and / or pathologies. In particular, this example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously enable the treatment of aphthous ulcers, gingivitis, and mucositis, thereby promoting the repair and / or improvement of the appearance and / or structure of mucous membranes. IVIA / a / ZUZΊ / UUOO I ¿ oral. 111 Example 13: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the treatment of disorders of the locomotor system (joint, tendons, ligaments, intervertebral discs) and mandibular joint In this example, the formulations used combine RGTA OTR4120 or OTR4131 at 10 pg / ml with hyaluronic acid normally used at preferred concentrations of 10 to 25 mg / ml such as those used in Example 5. The composition is applied by injection near the injured area or directly at the site of the injury, for example, intra-articularly if the injury is osteoarticular chondral, or intratendinous, peritendinous, or intramuscular in the case of a tear or rupture. The products of the invention readily diffuse into and around the area of ​​the injury, filling the space created by the lesion. The treated individuals independently present a pathology and / or alteration of the musculoskeletal system, for example, at the level of the joints, i.e., as in arthritis of the knee or hip or temporary mandibular disorders, at the level of the tendons, namely partial ruptures of tendon fibers or ligaments as described by Jacquet-Guibon S, 2018

[20] with the OTR4131 products in sport horses or in the review by Barritault D et al.

[18] in particular in the fusion of vertebrae

[18] or proximal injection at the level of the intradiscal area or in the thesis of Carnicer 112 David, Preliminary report-ultrasound evolution of tendon injuries treated with RGTA in horses, Ecole Nationale Vétérinaire de Maison Alfort, February 2009

[36] , at the level of the ligaments in an example of mandibular joint disorders treated by injection in the area at the periarticular level near the fibrocartilaginous articular disc, the disc ligaments and the mandibular muscles or also at the level of the intervertebral discs, i.e., the flattening zone of an intervertebral disc (Ll). In these treatments, the result and effect is rapid, in particular an immediate disappearance of pain, and advantageously the effect is long-lasting, more than a year, particularly in combination with a topical application of an example composition according to the invention, in particular the cream described in example 6, advantageously comprising polymers of small molecular weights, for example, from 3000 to 6000 daltons associated with AH or not. Advantageously, the results obtained and the effects with an example of a composition according to the invention are superior to those obtained with the use of RGTA alone as described in the study Jacquet-Guibon S, 2018

[20] or Carnicer

[36] . Furthermore, a particularly beneficial, surprising, and unexpected effect has been observed for an injectable preparation for the treatment of joint and tendon injuries. The same occurred in a case of 113 pain related to intervertebral disc injuries, the pain having disappeared without recurring after more than a year. This example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for the treatment of pathologies and / or conditions of the musculoskeletal system. In particular, this example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for the treatment of joint and tendon injuries, pathologies related to the intervertebral disc, such as disc compression or disc injury, by restoring its structure and / or promoting its healing.Furthermore, this example also clearly demonstrates that composition examples according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously allow for the synergistic treatment of pain, for example, pain associated with intervertebral disc injuries. Example 14: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the treatment of periodontal diseases In this example, the composition used is regardless of whether it is described in Examples 5 or 13. The composition is used 114 independently, particularly in local application to the lesion by filling, injection of periodontal pockets, bone grafts. The composition is injected directly into the gums or periodontal pocket area or deposited into this pocket. After application, the composition according to the invention allowed for better absorption of periodontal lesions or grafts than that observed with products based on the polymeric formula AaXxYy or AaXxYyZz used alone. Furthermore, advantageously, an example of a composition according to the invention has advantageously enabled the treatment of periodontal pathologies, in particular a filling of the deficiency of supporting tissues of the teeth and a restoration of the gums. Furthermore, the results obtained using an example of a composition according to the invention show better efficacy and, unexpectedly, a synergistic effect in the treatment compared to the results obtained with the revised RGTA alone, e.g., as described in Barritault. D et al. 2017

[18] or, in the opinion of experts in the field, compared to the results obtained with AH alone. Example 15: Toothpaste comprising polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid The composition according to the invention comprising a biocompatible polymer and hyaluronic acid can 115 Easily incorporate into all types of toothpastes and use for topical application as toothpaste. In this example, toothpastes are pastes, particularly for twice-daily use, that independently comprise an RGTA OTR4120 or OTR4131 concentration of 1 pg / mL and a hyaluronic acid concentration of 20 mg / mL. Toothpaste is particularly useful for twice-daily use and advantageously allows for the treatment and / or prevention of periodontal diseases. Example 16: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the treatment of fibrosis, an example of tissue adhesions In this example, compositions comprising an RGTA OTR4120 or OTR4131 concentration of 10 pg / ml and a hyaluronic acid concentration of 5 to 20 mg / ml are used. As demonstrated in Example 2, RGTAOTR4120 or OTR4131 at 10 pg / mL combined with hyaluronic acid has a synergistic effect not only to decrease the amount of Collagen 3 overexpressed in fibrosis but to increase that of Collagen 1 to obtain a COL3 / COL1 ratio very similar to that of normal tissue, but also because of its ability to promote secretion on the basal side and not on the apical side. This property of the mixture is particularly noticeable when using the product of the invention in the form of atomization. 116, for example, as described in Examples 6, 10, and 12, for application after open surgery. For example, after laparotomy, by coating tissues and organs with an atomization spray before closure, or when introducing an implant, such as a pacemaker, prosthesis, or catheter, where the connective tissue adhesion will decrease over time. In these indications, the use of atomization has proven to be very effective and has been demonstrated, in particular, in a patient who underwent a second laparotomy. This example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously prevent and / or treat fibrosis. In particular, this example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid advantageously prevent the formation of adhesion plaque, for example, in the abdomen, following abdominal surgery. Example 17: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the treatment of fibrosis In this example, compositions comprising an RGTA OTR4120 or OTR4131 concentration of 10 pg / ml and a hyaluronic acid concentration of 0.1 to 2 mg / ml are used. IVIA / a / ZUZΊ / UUOO I ¿ 117 In this example, fibrous tissues are fibrous tissues present particularly in ischemic muscle or in the brain. The administration of the compositions is carried out in accordance with the usual methods known to those experienced in the technique. RGTA is known for its protective and antifibrotic effects on functional recovery of ischemic muscle [26; 27] or brain (Theranostics. 2018 Nov 12; 8 (21): 5814-5827. Doi: 10.7150 / thno.28252. ECollection 2018., A heparan sulfate-based matrix therapy reduces brain damage and improves functional recovery after stroke Khelif Y, Toutain J, Quittet MS, Chantepie S, Laffray X, Valable S, Divoux D, Sineriz F, Pascolo-Rebouillat E, Papy-Garcia D, Barritault D, Touzani O, Bernaudin M.

[31] ). In this example, the combination of RGTA, for example, OTR4120 or 4131 with hyaluronic acid will also have a synergistic effect in the treatment of fibrosis and in addition to the functional recovery of the treated fibrotic muscle. This example clearly demonstrates that compositions according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid can advantageously treat fibrosis, particularly muscle fibrosis. In particular, this example clearly demonstrates that compositions according to the invention 118 with the invention comprising a polymer of formula AaXxYy or AaXxYyZz and hyaluronic acid can advantageously prevent the formation of fibrosis by improving the functional recovery of tissue, for example, fibrotic muscle. Example 18: Use of polymers of formula AaXxYy or AaXxYyZz and hyaluronic acid in the treatment of degenerative diseases. In this example, compositions comprising an RGTA OTR4120 or OTR4131 concentration of 10 pg / ml and a hyaluronic acid concentration of 0.1 to 2 mg / ml are used. RGTA is also known for its effects in the treatment of neurodegenerative diseases (EP 12305414

[32] ), particularly by intra-arterial or intracerebral administration of RGTA. The administration of the compositions is carried out in accordance with the usual methods known to those experienced in the technique, in particular by intra-arterial or intracerebral administration. The subjects present in particular neurodegenerative diseases, for example, as described in document EP 12305414

[32] . In this example, the combination of RGTA, for example, OTR4120 or 4131 with hyaluronic acid will also have a synergistic effect in the treatment of neurodegenerative diseases. 119 List of references 1. Modified hyaluronic acid based materials for biomedical applications. Tiwari S, Bahadur P.Int J Biol Macromol. Enero de 2019;121:556-571. doi: 10.1016 / j.ijbiomac.2018.10.049. Epub 2018 Oct 12. Review. 2. Hyaluronic acid, a promising skin rejuvenating biomedicine: A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, Khan S, Sohail M, Ramli NA, Thu HE, Hussain Z. Int J Biol Macromol.2018 Dec;120(Pt B) :1682- 1695 . doi: 10.1016 / j.ijbiomac.2018.09.188. doi:10.1016 / j.ijbiomac.2018.09.188. 3. Reduction of postoperative adhesión development. Diamond MP. Fértil Steril. 2016 Oct; 106 (5) :994-997.el. doi: 10.1016 / j.fertnstert.2016.08.029. Epub 2016 Sep 10. Review. 4. Documentos de patente US06689741, US2014301972A1 5. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P. Gut.2004 Jan;53(1):85-90. 6. Insights on a new path of pre-mitochondrial apoptosis regulation by a glycosaminoglycan mimetic. Yue XL, Lehri S, Li P, Barbier-Chassefiére V, Petit E, Huang QF, Albanese P, Barritault D, Caruelle JP, Papy-Garcia D, Morin C. Cell Death 120 Differ.2009 May;16(5):770-81. doi: 10.1038 / cdd.2009.9 7. Differential effect triggered by a deparan mimetic of the RGTA family preventing oral mucositis without tumor protection. Mangoni M, Yue X, Morin C, Violot D, Frascogna V, Tao Y, Opolon P, Castaing M, Auperin A, Biti G, Barritault D, Vozenin-Brotons MC, Deutsch E, Bourhis J. Int J Radiat Oncol Biol Phys.2009 Jul 15; 74 (4): 1242-50 . doi: 10.1016 / j.ij robp.2009.03.006 8. RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin. Garcia-Filipe S, Barbier-Chassefiere V, Alexakis C, Huet E, Ledoux D, Kerros ME, Petit E, Barritault D, Caruelle JP, Kern P J Biomed Mater Res A.2007 Jan;80(l):75-8 9. Documento de patente EP1677807 10. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. Rouet V, Meddahi-Pellé A, Miao HQ, Vlodavsky I, Caruelle JP, Barritault D. J Biomed Mater Res A.2006 Sep 15; 78 (4) : 792-7 11. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. Int J Biol Macromol.1996 Feb;18(l-2):141-5. 12. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck W, Μλ / 3 / ZUZΊ / UUOO I ¿ 121 Caruelle JP. J Biol Chem.2000 Sep 22; 275 (38) : 29383-90 13. Heparan sulfate mimetics modulate calpain activity during rat Soleus muscle regeneration. Zimowska M, Szczepankowska D, Streminska W, Papy D, Tournaire MC, Gautron J, Barritault D, Moraczewski J, Martelly I. J Cell Physiol. 2001 Aug; 188 (2) :178-87 . 14. RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Barritault D, Gilbert-Sirieix M, Rice KL, Siñeriz F, PapyGarcia D, Baudouin C, Desgranges P, Zakine G, Saffar JL, van Neck J. Glycoconj J.2017 Jun; 34 (3) :325-338. doi: 10.1007 / s10719-016-9744-5 15. Tammi R., Agren UM., Tuhkanen AL., Tammi M. Hyaluronan metabolism in skin. Progress in Histochemistry & Cytochemistry.29 (2) :1-81, 1994 16. R. Stern et al., European Journal of Cell Biology 58 (2006) 699-715) 17. Yasunori I. et al., Biomaterials 2011, 32 :769e776) et Petit E. et al., Biomacromolecules.2004 Mar-Apr; 5(2):44552 . 18. RGTA®-based matrix therapy - A new branch of regenerative medicine in locomotion. Barritault D, Desgranges P, Meddahi-Pellé A, Denoix JM, Saffar JL. Joint Bone Spine.2017 May;84(3):283-292. doi: 10.1016 / j.jbspin.2016.06.012. 19. Frescaline G. et al., Tissue Eng Part A. 2013 122 Jul;19(13-14):1641-53. doi: 10. 1089 / ten.TEA.2012.0377). 20. Randomized controlled trial demónstrales the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses. Jacquet-Guibon S, Dupays AG, Coudry V, Crevier-Denoix N, Leroy S, Siñeriz F, Chiappini F, Barritault D, Denoix JM. PLoS One.2018 Mar 9;13(3):eO191796. doi: 10.1371 / j ournal.pone.0191796 21. Reparan sulfate proteoglycans medíate internalization and propagation of specific proteopathic seeds. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, PapyGarcia D, Diamond MI. Proc Nati Acad Sci USA. 2013 Aug 13;110 (33) :E3138- 47. doi: 10.1073 / pnas.1301440110 22. Structure-activity studies of heparan mimetic polyanions for anti-prion therapies. Ouidja MO, Petit E, Kerros ME, Ikeda Y, Morin C, Carpentier G, Barritault D, BrugérePicoux J, Deslys JP, Adjou K, Papy-Garcia D. Biochem Biophys Res Commun.2007 Nov 9; 363 (1) :95-100. 23. In Vitro Evaluation of the Sensitivity of a Hyaluronic Acid PEG Cross-Linked to Bovine Testes Hyaluronidase Nicola Zerbinati et al. Open Access Maced J Med Sci. 2018 Jan 25; 6(1):20-24 https: / / doi.org / 10.3889 / oamjms.2018 24. Salí I, Férard G. Comparison of the sensitivity of 11 crosslinked hyaluronic acid gels to bovine testis IVIA / a / ZUZΊ / UUOO I ¿ 123 hyaluronidase. PolymDegrad Stab. 2007; 92: 915-919. https: / / doi.org / 10.1016 / j.polymdegradstab.2006.11.020. 25. Reissig JL, Strominger JL, Leloir LF. A modified colorimetric method for the estimation of N-acetylamino sugars. J Biol Chem 1955;217:959e96. 26. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. FASEB J.1999 Apr;13(6) :761-6. 27. New agents for the treatment of infarcted myocardium. Yamauchi H, Desgranges P, Lecerf L, Papy-Garcia D, Tournaire MC, Moczar M, Loisance D, Barritault D. FASEB J.2000 Nov;14 (14) :2133-4. 28. Asselot-Chapel C et al. Expression of fibronectin and interstitial collagen genes in smooth muscle cells: modulation by low molecular weight heparin fragments and serum.Biochem Pharmacol.1995 Mar 1;49(5):653-9. 29. Evaluation of a new matrix regenerating agent in patients with Sjbgren syndrome and superficial ulcerative keratitis resistant to conventional therapy: A report of 3 cases. Fajnkuchen F, Barritault D, Giocanti-Aurégan A. Medicine (Baltimore).2018 Mar;97(10):e9935. doi: 10.1097 / MD.0000000000009935. 30. A Rapid Responso to Matrix Therapy With RGTA in Severe Epidermolysis Bullosa. Malaq AA, Barritault D. 124 Eplasty.2012;12:icl5. 31. Theranostics.2018 Nov 12; 8 (21) :5814-5827 . doi: 10.7150 / thno.28252. eCollection 2018., A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke. Khelif Y, Toutain J, Quittet MS, Chantepie S, Laffray X, Valable S, Divoux D, Sineriz F, Pascolo-Rebouillat E, Papy-Garcia D, Barritault D, Touzani O, Bernaudin M. 32. EP 12305414 33. Jammed Microgel Inks for 3D Printing Applications., Highley CB, Song KH, Daly AC, Burdick JA. Adv Sci (Weinh). 2018 Oct 24,-6(1):1801076. doi: 10.1002 / advs . 201801076 . 34. Collagen / heparin sulfate scaffolds fabricated by a 3D bioprinter improved mechanical properties and neurological function after spinal cord injury in rats. Chen C, Zhao ML, Zhang RK, Lu G, Zhao CY, Fu F, Sun HT, Zhang S, Tu Y, Li XH. J Biomed Mater Res A. 2017 May;105(5):1324-1332. doi: 10.1002 / jbm.a.36011. Epub 2017 35. Development and Evaluation of Hyaluronic Acid-Based Hybrid Bio-Ink for Tissue Regeneration. Lee J, Lee SH, Kim BS, Cho YS, Park Y.Tissue Eng Regen Med. 2018 Sep 21; 15 (6) : 7 61769. doi: 10.1007 / sl3770-018-0144-8 . eCollection 2018 Dec. 36. Carnicer David, Preliminary report- ultrasonographic evolution of tendón lesions treated with RGTA in horses, Ecole Nationale Vétérinaire de Maison Alfort, Février 2009. MA / a / ZUZI / UUOO I z 125 It is hereby stated that, as of this date, the best method known to the applicant for putting the aforementioned invention into practice is the one that is clear from the present description of the invention.

Claims

CLAIMS Having described the invention as above, the following claims are claimed as property:

1. A pharmaceutical or dermatological composition for use as a medicament, characterized in that it comprises: a biocompatible polymer of the following general formula AaXxYy (I) wherein A represents a monomer, X represents an R1COOR2 or -R9(C=O)Rio group, Y represents an O or N-sulfonate group and corresponds to one of the following formulas: -R3OSO3R4, -R5NSO3R6, R7SO3R8 wherein: Ri, R3, R5 and R9 independently represent an optionally branched and / or unsaturated aliphatic hydrocarbon chain and optionally containing one or more aromatic rings, with the exception of benzylamine and benzylamine sulfonate, R2, R4, Re and Rs independently represent a hydrogen atom or a cation, R7 and Rio independently represent a bond, a chain of optionally branched and / or unsaturated aliphatic hydrocarbon,a represents the number of monomers, x represents the degree of substitution of monomers A MA / a / ZUZI / UUOO I z 127 by groups X, and y represents the degree of substitution of monomers A by groups Y, and hyaluronic acid.

2. Non-therapeutic or dermatological cosmetic use of a composition comprising a biocompatible polymer of the following general formula AaXxYy (I) wherein: A represents a monomer, X represents an R1COOR2 or -Rg(C=O)Rio group, Y represents an O or N-sulfonate group and corresponds to one of the following formulas: -R3OSO3R4, -R5NSO3R6, R7SO3R8 wherein: Ri, R3, R5 and R9 independently represent an optionally branched and / or unsaturated aliphatic hydrocarbon chain and optionally containing one or more aromatic rings, excluding benzylamine and benzylamine sulfonate, R2, R4, Re and Rs independently represent a hydrogen atom or a cation, R7 and Rio independently represent a bond, an optionally branched and / or unsaturated aliphatic hydrocarbon chain, a represents the number of monomers, x represents the degree of substitution of the monomers A by groups X, 128 and represents the degree of substitution of monomers A by groups Y,and hyaluronic acid.

3. The composition for application or use in accordance with any of claims 1 to 2, wherein the identical or different A monomers are selected from sugars, esters, alcohols, amino acids, nucleotides, nucleic acids, proteins or derivatives thereof.

4. The composition for application or use in accordance with any of claims 1 to 3, wherein the identical or different A monomers are selected from sugars or derivatives thereof.

5. The composition for application or use in accordance with any one of claims 1 to 4, wherein a maximum of 20% of the monomers A are independently monomers of the following formula: vwO R10 wherein Rg and Rio independently represent an oxygen atom, an optionally branched and / or unsaturated aliphatic hydrocarbon chain, a heteroaryl group independently comprising one or more oxygen and / or nitrogen atoms, 129 an aldehyde functional group, a carboxylic acid group, a diol, a substituted diol, a group of formula -Rn- (X) n_Ri2 wherein Rn represents an optionally branched and / or unsaturated aliphatic carbon chain from C1 to C4, X represents a heteroatom selected from oxygen and nitrogen, n is an integer from 1 to 4, and R12 is a hydrogen atom, an optionally branched and / or aliphatic hydrocarbon chain unsaturated, a heteroaryl group independently comprising one or more oxygen and / or nitrogen atoms,an aldehyde functional group, a carboxylic acid group, a diol, a substituted diol.

6. The composition for application or use in accordance with any of claims 1 to 5, wherein the number of monomers a is such that the mass of such polymers of formula (I) is greater than or equal to 3000 daltons.

7. The composition for application or use in accordance with any of claims 1 to 6, wherein the degree of substitution x is between 10 and 150%.

8. The composition for application or use in accordance with any of the preceding claims, wherein the degree of substitution is between 10 and 170%.

9. The composition for application or use in accordance with any of the preceding claims, wherein the radical R is selected from an alkyl, allyl, aryl, linear, or branched group. 130 10. The composition for application in accordance with any of the preceding claims, characterized in that the biocompatible polymer further comprises functional chemical groups Z, other than X and Y, capable of conferring additional biological or physicochemical properties upon the polymer.

11. The composition for application according to claim 10, characterized in that the degree of substitution z of all monomers A by Z groups is from 1 to 50%.

12. The application composition according to claim 10 or 11, characterized in that group Z is a substance capable of conferring to such polymers improved solubility or lipophilicity.

13. The application composition according to claim 12, characterized in that the Z groups are identical or different and are selected from the group comprising amino acids, fatty acids, fatty alcohols, ceramides or derivatives thereof or alternatively targeting nucleotide sequences.

14. The composition for use in accordance with any of claims 6 to 13, wherein the Rg and Rio groups are independently and optionally replaced by a Z group.

15. The composition for use according to claim 1 or according to any of claims 3 to 14 when dependent on claim 1, wherein the medicament is for the treatment of tissue damage and / or dryness and / or tissue damage, fibrosis.

16. The composition for use according to claim 1 or according to any of claims 3 to 14 when dependent on claim 1, wherein the medicament is for the prevention and / or treatment of diseases and / or pathologies selected from the group of fibrosis, tissue damage, pathologies and / or conditions of the musculoskeletal system, retinal detachment and / or treatment of age-related macular degeneration, dry age-related macular degeneration, wet age-related macular degeneration, tissue dryness, dryness of mucous membranes, epidermolysis bullosa, periodontal diseases, diseases of the oral mucosa, burns, degenerative diseases.

17. The composition for use according to claim 1, or according to any of claims 3 to 14 when dependent on claim 1, wherein the medicament is for the treatment of skin lesions.

18. The composition for use according to claim 1, or according to any of claims 3 to 14 when dependent on claim 1, wherein the medicament is for the treatment of a degenerative disease.

19. The composition for use according to claim 2, or according to any of claims 3 to 14 when dependent on claim 2, wherein the non-therapeutic cosmetic use is an anti-aging use and / or for the protection of the skin from external aggressions and / or for the treatment and / or prevention of skin aging.

20. The use of a pharmaceutical composition, comprising: i. a biocompatible polymer of the following general formula AaXxYy (I) wherein: A represents a monomer, X represents an R1COOR2 group, Y represents an O or N-sulfonate group and corresponds to one of the following formulas: -R3OSO3R4, -R5NSO3R6, R7SO3R8 wherein: Ri, R3, R5 and R9 independently represent an optionally branched and / or unsaturated aliphatic hydrocarbon chain and optionally containing one or more aromatic rings except for benzylamine and benzylamine sulfonate, R2, R4, Re and Rs independently represent a hydrogen atom or a cation, Rv and Rio independently represent a bond, an optionally branched and / or unsaturated aliphatic hydrocarbon chain, a represents the number of monomers, x represents the degree of substitution of the monomers A by the groups X, and represents the degree of substitution of monomers A by groups Y, and ii.hyaluronic acid for the manufacture of a medicine.

21. The non-therapeutic cosmetic use of a composition, comprising: i. a biocompatible polymer of the following general formula AaXxYy (I) wherein: A represents a monomer, X represents an R1COOR2 group, Y represents an O or N-sulfonate group and corresponds to one of the following formulas: -R3OSO3R4, -R5NSO3R6, R7SO3R8 wherein: Ri, R3, R5 and R9 independently represent an optionally branched and / or unsaturated aliphatic hydrocarbon chain and optionally containing one or more aromatic rings except for benzylamine and benzylamine sulfonate, R2, R4, R0 and Re independently represent a hydrogen atom or a cation, R7 and Rio independently represent a bond, an optionally branched and / or unsaturated aliphatic hydrocarbon chain, a represents the number of monomers, x represents the degree of substitution of the monomers A by the X groups, and y represents the degree of substitution of the monomers A by groups Y, and ii. hyaluronic acid.